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ABSTRACT 
Hyperhomocysteinaemia is a recently established risk factor for the development of vascular 
disease and is caused by a variety of defects in the metabolism of methionine as well as 
dietary deficiencies of the vitamin cofactors (B6, B12 and folate) of the enzymes involved in 
methionine metabolism. Cystathionine j3-synthase (CBS) is the most common genetic cause 
of homocystinuria, the severe form of the disease. The incidence of CBS deficiency in a 
group of 12 young patients of varied ethnic origin, who had peripheral vascular disease (PVD) 
that could not be ascribed to any of the conventional risk factors and were selected for having 
hyperhomocysteinaemia, either in the fasting state or after methionine load, was investigated. 
Nine out of the ten patients tested, showed abnormally elevated plasma homocysteine levels 
after methionine load, indicating a high incidence of deficient transsulfuration, which may 
have been caused by defects in CBS. 
Very wide variation in the CBS assay has hampered efforts to establish the contribution of 
CBS deficiency to the hyperhomocysteinaemia observed in this population. Therefore, a 
major part of this work has focussed on the source of this variation and the data suggests that 
between experiment variation as a result of changes in enzyme activity during the culture of 
the fibroblasts makes the biggest contribution. The most appropriate criterion to identify 
heterozygotes for CBS deficiency under these circumstances is to measure reduced CBS 
activity on several separate occasions compared to a control group. Only one of the group of 
12 PVD patients (patient 1000) was identified as a heterozygote for CBS deficiency using this 
standard. Heterozygosity for CBS deficiency therefore seems to make only a minor 
contribution to the observed hyperhomocysteinaemia in this group of patients. 
Molecular genetic investigations were performed on selected individuals. Patient 1000 was 
confirmed to be a heterozygote for CBS deficiency. An A to G transition at nucleotide 695 
leading to histidine to arginine substitution at amino acid 232 was found in one allele of this 
patient. A young homocystinuric female (patient 960) was confirmed to be compound 
heterozygote for CBS deficiency, with the common Celtic G91 gA transition on the one allele 
and a novel duplication of the 7 bases between position 1553 and 1559 on the other allele. 
This 7bp insertion was identified as coming from the mother (patient 961 ). 
In an attempt to find an alternative or perhaps more sensitive method for the detection of 
defects in methionine metabolism, dual metabolic labelling of cultured fibroblasts with 
L-[methyl-3H]-methionine and L-[3
5S]-methionine was developed to investigate these pathways 
in homozygotes and heterozygotes for CBS deficiency compared to controls. Although, no 
differences in the ratio of 
3Ht35S were found that could be used to identify the zygosity of the 
patient for CBS deficiency, changes in the ratio of 
3Ht35S over time in certain cellular 
compartments suggest that further development of this approach may prove to be useful. 
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Homocysteine is an amino acid intennediate of methionine metabolism, which is illustrated in 
figure 1 and has been reviewed extensively (Mudd et al, 1995 and Finkelstein, 1990). 
Methionine, ingested through the diet or produced by protein catabolism is combined with the 
adenosyl moiety of ATP to produce S-adenosylmethionine (SAM). This reaction is catalyzed 
by ATP:L-methionine S-adenosyl transferase (EC 2.5.1.6) (MAT) (1) and is irreversible under 
physiological conditions due to the enzymatic cleavage of the remaining enzyme-bound 
tripolyphosphate. SAM is utilized in a variety of methylation reactions (2), yielding a 
methylated acceptor and S-adenosylhomocysteine. SAM plays a pivotal role in the C- and N-
tenninal methylation of proteins, a variety of methylation reactions on RNA and DNA as well 
as phospholipids (Chiang et al, 1996). S-adenosylhomocysteine is cleaved to adenosine and 
homocysteine by S-adenosylhomocysteine hydrolase (EC 3.3.1.1) (3). The equilibrium of this 
reaction favours the fonnation of S-adenosylhomocysteine, but rapid utilization of both 
homocysteine and adenosine allows the reaction to proceed in the direction of cleavage 
under physiological conditions. 
Homocysteine can either be remethylated to methionine or utilized in the transsulfuration 
pathway to produce cysteine. In the liver, flux is divided equally through the remethylation 
and transsulfuration pathways under steady state conditions (Finkelstein and Martin, 1984), 
with flux through the transsulfuration pathway being increased in response to excess 
methionine (Finkelstein and Martin, 1986). 
Remethylation of homocysteine can occur from two methyl group donors. 
Betaine:homocysteine methyltransferase (EC 2.1.1.5) (4) transfers a methyl group from 
betaine to homocysteine, producing methionine and N,N-dimethylglycine. 5-methyl 
tetrahydrofolate:homocysteine methyltransferase (EC 2.1.1.13) (methionine synthase) (5), a 
cobalamin dependant enzyme, utilizes 5-methyl tetrahydrofolate as a methyl donor and this 
reaction links methionine metabolism to the folate cycle. Tetrahydrofolate is produced after 
the methyl group transfer and is itself methylated by serine hydroxymethyl transferase (6) 
which transfers the methyl moiety from serine, yielding glycine and 5, 10-methylene 
tetrahydrofolate. 5'-Methyl tetrahydrofolate is refonned by 5, 10-methylene tetrahydrofolate 
reductase (EC 1.1.99.15) (MTHFR) (7). 
Homocysteine is committed to the transsulfuration pathway through the condensation of 
serine with homocysteine by L-serine hydro-lyase (adding homocysteine) (EC 4.2.1.22) 
(cystathionine P-synthase) (CBS) (8), a reaction that is dependent on pyridoxal 5-phosphate 
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Figure 1. Summary of the pathways of methionine metabolism. The enzymes are numbered as 
follows: ( 1) ATP: L-methionine S-adenosyl transferase, (2) methyl transferase, 
(3) S-adenosylhomocysteine hydrolase, (4) betaine:homocysteine methyltransferase, (5) 5-methyl 
tetrahydrofolate: homocysteine methyltransferase, (6) serine hydroxymethyl transferase, 
(7) 5, 10-methylene tetrahydrofolate reductase, (8) cystathionine f1-synthase, (9) y-cystathionase. 
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L-cystathionine cysteine-lyase (deaminating) (EC 4.4.1.1) (y-cystathionase) (9), another 
vitamin B6 dependant enzyme. Cysteine is utilized for protein anabolism and excess cysteine 
metabolized to taurine and excreted as sulfate. This allows the transsulfuration pathway to 
act as a route for the disposal of excess methionine. S-adenosylmethionine plays a major 
regulatory role in the metabolism of methionine and tightly controls its own concentration. 
SAM acts allosterically on MAT, betaine:homocysteine methyltransferase, CBS and MTHFR. 
High levels of methionine result in increased levels of SAM which in tum activates MAT and 
CBS, and inhibits MTHFR and betaine:homocysteine methyltransferase, thereby increasing 
flux through the transsulfuration pathway and inhibiting the remethylation of homocysteine to 
methionine. Methionine also regulates its own concentrations by inhibiting methionine 
synthase and betaine:homocysteine methyltransferase (Finkelstein, 1990 and Selhub and 
Miller, 1992) 
Homocystinuria and hyperhomocysteinaemia 
Homocystinuria was first described in 1962 by Gerritsen and coworkers, who observed 
subjects who excreted homocystine in their urine and had markedly elevated levels of plasma 
homocystine and methionine. The normal range for homocysteine measured in serum or 
plasma obtained from subjects in the fasting state has been established by a variety of 
studies as between 5 and 15µM (Ueland et al, 1993). These measurements reflect the total 
amount of homocysteine in blood, of which 80% is bound to protein, with the remaining 20% 
present as disulfides with itself or cysteine, and a minute fraction in the thiolactone form. 
Increased intracellular homocysteine is managed by export out of cells (Svardal et al, 1986) 
allowing serum or serum homocysteine levels to be utilized as a measure of the status of 
intracellular homocysteine metabolism. Mild, intermediate and severe 
hyperhomocysteinaemia have been defined as 15 to 30µM, 30 to 1 OOµM and >1 OOµM 
respectively (Kang et al, 1992). 
Factors causing homocystinuria and hyperhomocysteinaemia 
Homocystinuria and hyperhomocysteinaemia can arise as a result of a great variety of causes 
including genetic defects in cystathionine beta-synthase, methionine synthase or methylene 
tetrahydrofolate reductase, dietary deficiencies of the cofactors involved in the cycle, namely 
vitamin B6, vitamin B12 and folate as well as defects in the activation and metabolism of 
these vitamin cofactors and certain disease states and medication (Mudd et al, 1995). 
Cystathionine /3-synthase deficiency 
Homozygosity for cystathionine ~-synthase deficiency has been established as the most 
common cause of homocystinuria, detected with a frequency of 1/300 000 live births by 
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newborn screening. CBS deficiency leads to an increase of both serum homocysteine and 
methionine and a decrease in cysteine (Mudd et al, 1995). Not long after homocystinuria was 
initially described, CBS deficiency was identified as the cause thereof (Mudd et al, 1965). 
The authors determined CBS activity in human liver obtained post-mortem and by biopsy 
measuring the conversion of 14C-serine to 
14C-cystathionine. Patients with homocystinuria 
showed virtually no CBS activity and normal methionine synthase and y-cystathionase activity 
in extracts of liver biopsy material. CBS activity measured in lysates of cultured fibroblasts 
obtained from human skin and cells in amniotic fluid was also shown to be decreased in 
homocystinuric patients compared to controls (Uhlendorf and Mudd, 1968), and fibroblasts 
are now commonly used to measure CBS activity. The measurement of CBS activity in 
lysates of phytohaemagglutinin stimulated lymphocytes obtained from blood has also been 
reported (Goldstein et al, 1972). 
The detection of homozygotes for CBS deficiency is easy, as patients have markedly 
increased plasma homocysteine levels and there is very little measurable enzyme activity in 
lysates of liver biopsy material or cultured cells. The identification of heterozygotes poses a 
greater problem as the mutations leading to decreased activity show great heterogeneity 
causing significant overlap in the ranges of fasting plasma homocysteine levels as well as the 
CBS activities between heterozygotes and normal subjects. The methionine loading test, in 
which subjects are fed an oral dose of 0.1 mg/kg body weight of L-methionine and 
homocysteine measured after 4 to 6h, was developed to identify heterozygotes for CBS 
deficiency by placing a load on the transsulfuration pathway (Fowler et al, 1971 ). The 
methionine-loading test however suffers from the same problem of overlap in the ranges of 
plasma homocysteine levels between heterozygotes and control subjects. Various attempts 
have been made to optimize the detection of heterozygotes, but none so far have provided 
satisfactory discrimination (McGill et al, 1990). The problem is further compounded by the 
fact that subjects heterozygous for the exact same genetic mutation in the CBS gene may 
show different phenotypes in terms of serum homocysteine levels (Dawson et al, 1996). 
Obligate heterozygotes for CBS deficiency have between 20 and 45 percent of the mean 
control activity measured in extracts of liver biopsy material and cultured fibroblasts, indicating 
negative interactions between normal and mutant subunits of the enzyme (Mudd et al, 1995). 
Certain homocystinuric patients show a decrease in plasma and urine homocysteine to 
normal or near normal levels in response to treatment with high doses of vitamin 66 (Barber 
and Spaeth, 1967) and this phenomenon is most likely due to stimulation of residual enzyme 
activity by excess co-factor (Mudd et al, 1970). In a survey of 629 homocystinuric patients, 
equal numbers appeared to be responsive and non-responsive to vitamin 66 therapy. Fowler 
et al (1978) provided evidence for variable response to pyridoxine treatment. They measured 
CBS activity in lysates of cultured fibroblasts obtained from pyridoxine responsive and 
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non-responsive patients and found that CBS activity was in some cases markedly
 increased, 
almost to normal levels, in some case only slightly increased and in some case not
 at all. 
Kraus and coworkers (1978) purified cystathionine ~-synthase from human liver a
nd showed 
that the enzyme exists as dimer with an apparent molecular weight of 94000, co
nsisting of 
two identical subunits with an apparent molecular weight of 48000. They determin
ed that the 
enzyme contains pyridoxal 5-phosphate as tightly bound cofactor by showing an a
bsorbance 
maximum at 427nm, typical of PLP containing enzymes and complete loss of ac
tivity upon 
treatment with hydroxylamine. The apparent Kn values for serine and homocysteine were 
determined as 1.15mM and 0.59mM respectively and the pH optimum was betwe
en 8.4 and 
9.0. These findings were refined by Skovby et al (1983), who illustrated tha
t the only 
transcriptional product of the CBS gene is a larger 63000 molecular weight su
b-unit that 
exists as a homotetramer. The dimer consisting of 48000 molecular weight sub-
units is the 
product of a slow post-translational proteolytic cleavage of the tetramer. The 
proteolytic 
cleavage to a smaller subunit occurred only in liver, and could not be detected in 
fibroblasts. 
The smaller subunit showed a 60-fold increase in specific activity and incubat
ion of liver 
extracts at 4°C for seven days led to a threefold increase in total enzyme ac
tivity. The 
increase in enzyme activity by post-translational cleavage is due to an increase in 
the affinity 
of the enzyme for homocysteine. Kraus (1987) showed that the appare
nt Km for 
homocysteine of the 63000 molecular weight sub-unit is 25mM, while it is 0.8m
M for the 
48000 molecular weight sub-unit. Partial trypsin cleavage of the enzyme lea
ds to the 
formation of the activated dimer with subunits of 45000 molecular weight, which is
 no longer 
sensitive to activation by S-adenosylmethionine, is less heat-stable than the tetram
er and has 
a three times higher affinity for homocysteine. Trypsin cleaves the CBS enzyme 
at Arg 413 
indicating that residues 414-551 are necessary for maintaining the tetrameric struc
ture of the 
enzyme (Kery et al, 1998). S-adenosylmethionine acts as an allosteric activat
or of CBS, 
increasing enzyme activity threefold (Kozich and Kraus, 1992), allowing SAM con
centrations 
to control the flux through the remethylation and transsulfuration pathways (Selhub
 and Miller, 
1992). In addition to the two substrates, and pyridoxal 5-phosphate
 and S-
adenosylmethionine, CBS also binds haem as a prosthetic group. The presence 
of haem is 
essential for PLP binding and each CBS subunit binds one molecule of haem
 and one 
molecule of PLP (Kery et al, 1994). The CBS cDNA has also been cloned and ex
pressed in 
E.coli, and the resulting protein product appears to be identical to the enzyme pu
rified from 
liver (Kozich and Kraus, 1992). 
The human CBS gene has been localized to the subtelomeric region of chromosom
e 21 by in 
situ hybridization of a rat cDNA probe (Munke et al, 1988) and the entire human C
BS cDNA 
has been sequenced (Kraus et al, 1993). The 2554bp cDNA coding for 551 amino
 acids was 
found to differentially retain a 214bp intron in the 3' noncoding sequence. Subs
equently, 4 
additional mRNA species differing only in the 5' untranslated regions were describe
d (Chasse 
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et al, 1995 and Bao et al, 1997). Bao et al (1997) illustrated the differential expression of the 
different isoforms in different tissues, suggesting a possible mechanism for maintaining 
different levels of translation between tissues. The rat CBS gene has been characterized, 
consisting of 17 exons, giving rise to four alternatively spliced mRNA's, two of which are 
catalytically active. The primary transcripts, type I and 111, differ by the presence or absence 
of the 42bp of exon 16, encoding two isoforms with different half-life (Swaroop et al, 1992 and 
Roper and Kraus, 1992). Recently, 28046bp encompassing the human CBS gene were 
sequenced and found to contain 23 exons ranging in length from 42 to 209bp (Kraus et al, 
1998). The coding region spans exon 1 through 16, with exon 15 being alternatively spliced, 
corresponding to the rat exon 16. Eleven out of the fourteen amino acids in exon 15 are 
conserved between human and rat and inclusion of exon 15 causes a threefold decrease in 
the half-life of the protein, but no change in kinetic properties, as was found for the rat exon 
16. 
Molecular analysis of several homocystinuric patients has revealed a great variety of 
mutations, which appear to be clustered in the amino terminal half of the protein in exons 2 to 
1 O (Kraus, 1994). Certain mutations have been found to occur more commonly than others 
do. The G to A transition at position 919 leading to the replacement of glycine 307 by serine 
(G307S), has been found to occur with a high frequency in patients of Celtic origin (Hu et al, 
1993). The mutation completely abolishes enzyme activity, although not affecting its 
immunoreactivity, and is associated with pyridoxine non-responsiveness in vivo. In a 
subsequent study, the G91 gA transition was found in 71 % of Irish homocystinuric patients 
(Galagher et al, 1995). The T to C transition at position 833 leading to the substitution of 
isoleucine 278 for threonine (1278T) (Kozich and Kraus, 1992) was detected in 7 out of 11 
pyridoxine responsive and O out of 27 pyridoxine non-responsive hyperhomocysteinaemic 
patients of varied ethnic backgrounds, and appears to be associated with a mild phenotype, 
even in the homozygous form (Shih et al, 1995). This mutation appears to occur with a high 
frequency in the Italian population and was found in 7 independent homocystinuric families 
out 14 tested (Sebastio et al, 1995). 
Not all apparently deleterious mutations in the CBS gene have pathological consequences. A 
68bp insertion at position 844 in exon 8 described by Sebastio et al (1995) was assumed to 
introduce a premature stop codon and to cause hyperhomocysteinaemia. This allele was 
also found to contain the pathogenic Ta33C transition. In a subsequent study however, this 
insertion was found in 11. 7% of the control population and normal size mRNA was found in 
individuals carrying the insertion. The authors speculated that the duplication of the intron 7 
splice acceptor by the insertion leads to the splicing out of both the insertion and the 
pathogenic point mutation and the production of functionally normal enzyme (Tsai et al, 
1996). Kluijtmans et al (1997) found the incidence of the insertion to be identical between 
patients with occlusive arterial disease and control subjects and found that the insertion was 
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not associated with hyperhomocysteinaemia, even in the homozygous form. An extensive 
study of the incidence of the insertion among several ethnic groups revealed that it occurs in 
the heterozygous form in 37.7% of blacks, 13.5% of Caucasians, <1% of Native Americans, is 
absent in Asians and was found to be always associated with the Ts33C transition (Franco, 
1998). 
The phenotypic features in hyperhomocysteinaemia have been found to correlate poorly with 
the genotype of the mutations. Dawson et al (1996) investigated a family, in which both 
parents of a homozygous child carried the G91 gA transition. The mother had well defined 
hyperhomocysteinaemia, ascertained by methionine loading while the father had normal 
serum homocysteine levels. Kraus (1994) described a case in which two compound 
heterozygote siblings with identical mutations showed markedly different progression of the 
disease. The sister was mentally retarded and showed skeletal abnormalities, while the 
brother was of normal intelligence and only had a single thrombotic episode by the age of 34. 
Kozich and Kraus (1992) also described a patient who had no appreciable CBS activity in 
fibroblast but suffered only from mild pyridoxine responsive homocystinuria. 
Defects in the synthesis of methionine 
Subjects deficient in methionine synthase activity suffer from homocystinuria, megaloblastic 
anemia and neurological abnormalities. Methionine synthase deficiency has been classified 
as a cobalamin disorder. The active form of the enzyme has the cobalt atom in the 1 + 
oxidation state and requires a different gene product to transfer an electron from NADPH to 
reduce it from the 2+ oxidation state after a number of catalytic cycles. This reduction can be 
achieved in vitro with thiol containing compounds such as dithiothreitol. Two forms of 
methionine synthase deficiency associated with low methylcobalamin have been 
characterized, based on complementation studies in cultured fibroblasts. Subjects with cblE 
display homocystinuria, but not methylmalonic aciduria and decreased methionine synthase 
activity is measured in fibroblasts only when assayed with low concentrations of reducing 
thiols. In subjects with cblG, low methionine synthase activity is measured even in the 
presence of high concentrations of reducing thiols. Deficient intracellular processing of 
cobalamin also leads to reduced methionine synthase activity and is classified as cblC or 
cblD. Methionine synthase has been isolated from human placenta and pig liver, exists as a 
monomer of 151000 to 155000 molecular weight, contains one mole of cobalt per mole of 
monomer and requires SAM for activity (Fowler, 1997 and Rosenblatt, 1995). The human 
methionine synthase cDNA has been cloned and the gene was localized to chromosome 
1q43 (Leclerc et al, 1996). The cDNA codes for a protein of 1265 amino acids and several 
mutations in the cDNA of patients in the cblG complementation have been group identified 
(Leclerc et al, 1996 and Wilson et al, 1998). 
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5, 10-methylenetetrahydrofolate reductase deficiency 
The major clinical features associated with 5, 10-methylenetetrahydrofolate reductase 
deficiency are developmental delay, psychiatric disturbances, seizures, abnormalities of gait 
as well as arteriosclerosis and thrombosis (Rosenblatt, 1995). Homocystinuria due to 
MTHFR deficiency was described in 1972 (Mudd et al) and subjects typically have low plasma 
concentrations of methionine and folate. The severity of the clinical features appear to be 
correlated with the degree of enzyme deficiency (Rosenblatt, 1995). MTHFR has been 
purified from human liver and was illustrated to exist as a homodimer consisting of subunits of 
75000 molecular weight. Each subunit contains one mole of flavin-adenine dinucleotide 
(FAD) which acts as an electron carrier from NADPH to its substrate (Zhou et al, 1990). The 
human liver MTHFR cDNA of 2200bp has been cloned and sequenced, coding for a 73600 
molecular weight protein which consists of 656 amino acids and the human gene has been 
mapped to chromosome 1 p36.3 (Goyette et al 1994). Several mutations in the coding 
sequence have been identified leading to varying degrees of enzyme deficiency. Kang et al 
(1988) have identified a thennolabile variant of MTHFR due to a C677 T transition leading to a 
valine to alanine substitution, that is associated with mild elevations in plasma homocysteine, 
and occurs in -10% of the Caucasian population (Rosenblatt, 1995). 
Vitamin levels and hyperhomocysteinaemia 
In the nonnal population, plasma levels of all three vitamin cofactors involved in homocysteine 
metabolism, vitamin 86, 812 and folate appear to influence serum homocysteine levels 
(Ubbink, 1997). A study of a nonnal elder1y population revealed negative correlations 
between plasma folate, 812 and pyridoxal 5-phosphate concentrations. Serum homocysteine 
levels showed the strongest association with plasma folate concentrations and 
hyperhomocysteinaemia was attributable to deficiency of one or more of the 8 vitamins in two 
thirds of the cases (Selhub et al, 1993). A Swedish study of 501 middle-aged subjects also 
showed a high correlation between serum homocysteine levels and plasma folate and 812 
concentrations (8rattstrom, et al 1994). The Hordaland homocysteine study, which 
investigated 11941 healthy subjects, showed that folate intake is one of the strongest 
determinants of serum homocysteine concentrations (Nygard et al, 1998). In a study of 44 
asymptomatic hyperhomocysteinaemic men 25% had reduced levels of plasma 86, 56.8% 
had reduced plasma 812 and 59.1% had reduced plasma folate (Ubbink et al, 1993). 
Subjects deficient in folate, 812 or 86 have abnonnal homocysteine metabolism as measured 
by either fasting serum homocysteine or post-methionine load serum homocysteine levels. 
Kang et al (1987) found that 84% of subjects with severe folate deficiency and 56% of 
subjects with low normal folate had higher than nonnal fasting serum homocysteine levels, 
while Stabler et al (1988) measured elevated fasting serum homocysteine in 18 out of 19 
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subjects with confinned folate deficiency. In a study by Brattstrom et al (1988) total plasma 
homocysteine in B12 deficient subjects was double that of controls and 40% of B12 deficient 
subjects had significant hyperhomocysteinaemia, while Stabler et al (1988) measured 
elevated fasting serum homocysteine in 77 out of 78 cobalamin deficient subjects. Vitamin 
B6 deficiency does not appear to raise fasting serum homocysteine levels significantly and 
supplementation with pyridoxine does not appear to be effective in decreasing fasting serum 
homocysteine levels in the general population (Miller et al, 1992). Deficiency of vitamin B6 
does however impair the transsulfuration pathway, as post-methionine load homocysteine 
levels were significantly higher in a group of theophyline treated asthmatic subjects compared 
to controls (Ubbink et al, 1996). Pyridoxine treatment lead to significant decreases in post-
methionine load serum homocysteine levels in both the control and theophyline treated 
asthmatics, but did not affect fasting serum homocysteine levels in either group. 
Pathological features associated with homocystinuria due to CBS deficiency 
The clinical abnonnalities associated with homocystinuria are many and involve the eye, 
skeletal, vascular and central nervous system (Gibson et al, 1964 and Schimke et al, 1965) 
and have been extensively reviewed by Mudd and coworkers (1995). Mudd and coworkers 
(1985) conducted an international survey of 629 patients suffering from homocystinuria due to 
cystathionine ~-synthase deficiency in an attempt to define the progression of these 
abnormalities. Clinical abnormalities appeared on average, much later in untreated B6 
responsive patients than in untreated B6 non-responsive patients. 
Dislocation of the optic lens is the most common clinical abnonnality associated with 
homocystinuria, a feature that it shares with Marfan syndrome. This is due to breaking of the 
zonular fibers that hold the lens in place. Mutations in the fibrillin gene, leading to structural 
instability of the protein have been identified as the cause of Marfan syndrome (Dietz et al, 
1992). Fibrillin is one of the main structural components of the zonular fibers and is rich in 
cysteine residues, which fonn disulfide bonds that are critical for maintaining the quaternary 
structure of the protein. The free thiol of homocysteine is thought to interfere with these 
disulfide bonds and ultimately lead to the destruction of the fibers. In the survey by Mudd 
(1985) most incidents of ectopia lentis appeared only after the age of 2 years and by age 38, 
97% of patients suffered from this condition. By 6 years of age 50% of the vitamin B6 non-
responsive patients had had one episode of ectopia lentis while this point was only reached 
by 10 years of age in the vitamin B6 responsive group. 
The skeletal abnonnalities that are observed include osteoporosis of the spine and long 
bones as well as lengthening and thinning of the long bones. Kang and Trelstad (1973) used 
the cross-linking of purified rat dennal collagen as an experimental system to investigate the 
effects of homocysteine on connective tissue. Their results indicated that soluble collagen did 
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not mature to fonn insoluble fibrils in the presence of homocysteine and that homocysteine 
interferes with intennolecular cross-link fonnation by reversibly binding aldehyde groups 
present in these molecules. They also discovered decreased cross-linking of dennal collagen 
in skin biopsies obtained from homocystinuric patients compared to controls. These findings 
could explain the effects of homocysteine on other collagen containing tissues, including 
bone. Lengthening and thinning of the long bones are typical Marfanoid features and could 
be explained by the effects of homocysteine on fibrillin, as is the case for ectopia lentis. Fifty 
percent of the 86 non-responsive patients show radiological evidence of spinal osteoporosis 
while the 50% mark is only reached by age 20 in the 86 responsive group (Mudd, 1985). 
Homocystinuric patients also tend to have decreased mental capabilities. The mean IQ for 
the 86 responsive group was 79 and for the 86 non-responsive group, 57. Seizures have 
been reported in about 20% of untreated patients with homocystinuria and appeared at a 
slightly higher frequency and somewhat earlier in 86 non-responsive patients than in 86 
responsive patients (Mudd et al, 1985). Abbott and coworkers (1987) evaluated 63 subjects 
with homocystinuria and discovered that 51 % of them suffered from clinically significant 
psychiatric disorders, indicating a very high incidence of mental illness among homocystinuric 
patients. A higher incidence of behavioral disorders was noted in the vitamin 86 
non-responsive group compared to the vitamin 86 responsive group. They also reported an 
overall lower average IQ (80 ± 27) for the homocystinuric patients compared to the general 
population and lower IQ in the vitamin 86 non-responsive patients compared to the vitamin 
86 responsive patients. 
Women suffering from homocystinuria appear to have decreased reproductive fitness. Data 
from the survey by Mudd and coworkers (1985) indicate that 1 O out of 55 pregnancies in 32 
women responsive to vitamin 86 ended in fetal loss. Male patients appear to have nonnal 
reproductive ability and out of 34 offspring produced by 21 males in the survey, 33 showed no 
clinical abnonnalities and only one spontaneously aborted. 
Thrombosis and atherosclerosis are two major clinical abnonnalities associated with 
homocystinuria and the greatest number of deaths in homocystinuric patients are as a result 
of infarcts due to thromboembolism. Mudd and coworkers (1985) examined 253 
thromboembolic events in 158 patients in their survey. Fifty one percent of the reported 
thromboembolic events affected peripheral veins of which 25% resulted in pulmonary 
embolism, 32% the cerebral vasculature, 11 % peripheral arteries, 4% resulted in myocardial 
infarctions and 2% were in none of the above categories. The cumulative risk for suffering 
from a thromboembolic episode was 25% by the age of 16 years and 50% by the age of 29 
years. The authors however cautioned that the numbers are only indicative of recorded 
events and that subjects had not been screened for the presence of possible early vascular 
damage. 
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The mechanism whereby homocysteine could potentially cause thrombosis and 
atherosclerosis has been the subject of much experimental attention. The initial observation 
of a relationship between homocystinuria and vascular damage was made by Mccully in 
1969, who described premature arterial thrombosis and atherosclerosis similar to what was 
observed in patients with CBS deficiency in an autopsy of a patient with homocystinuria due 
to a defect in vitamin 812 metabolism. This patient suffered from hyperhomocysteinaemia 
but not hypermethionineaemia, which led the author to conclude that increased homocysteine 
was associated with vascular damage. Subsequent studies have focussed the effect of 
homocysteine on endothelial cell damage, platelets, the clotting cascade and soluble factors. 
Homocysteine may have a direct toxic effect on the vascular endothelium. Wall et al (1980) 
provided in vitro evidence by illustrating the dose dependent release of 
51 Cr from monolayers 
of endothelial cell cultures in response to incubation with homocysteine. Similar results were 
obtained by Dudman et al (1991), who illustrated the detachment of cultured vascular 
endothelial cells in response to both homocysteine and cysteine. This detachment was 
however significantly inhibited when the cells were grown on fibronectin coated plates, casting 
doubt over the relevance of these findings in vivo. A possible role for hydrogen peroxide in 
endothelial damage was described by Starkebaum and Harlan (1986), who observed the 
copper dependant oxidation of homocysteine in human serum with the concomitant 
production of peroxide. Incubation of human and bovine endothelia cells with homocysteine 
in the presence of copper produced dose dependent cell lysis that was prevented by the 
addition of catalase. Increased homocysteine may also have an influence on the availability 
of nitric oxide (endothelial-derived relaxing factor), thereby decreasing endothelial response to 
increases in blood flow, which could eventually lead to atherosclerosis. Bovine aortic 
endothelial cells cultures showed a dose dependent decrease in nitric oxide in response to 
homocysteine, leading to the decreased ability of cells to detoxify peroxide. Nitric oxide 
synthase activity and transcription was unaffected indicating that the production of nitric oxide 
was not altered (Upchurch et al, 1997). 
Endothelial damage and dysfunction has also been observed in several animal models and 
studies on human subjects. Desquamation of -10% of the aortic endothelial surface was 
observed in baboons subsequent to a 3-month infusion of 200µM homocystine in the 
presence or absence of dipyridamole, an inhibitor of platelet function. A threefold increase in 
platelet consumption was observed as a consequence of endothelial damage and 
dipyridamole inhibition of platelet function did not alleviate desquamation. A threefold 
increase in platelet consumption and shortened platelet survival times was also measured in 
four homocystinuric patients compared to control subjects (Harker et al, 197 4). Intimal 
lesions containing proliferating smooth muscle cells surrounded by connective tissue was 
observed in the absence of dipyridamole but not in the presence thereof, suggesting that 
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platelet activation as a result of endothelial cell damage leads to arteriosclerosis (Harker et al, 
1976). The effect of homocysteine on the proliferation of cultured endothelial and smooth 
muscle was investigated by Tsai et al (1994). They observed a 25% increase in DNA 
synthesis in rat aortic smooth muscle cells in response to incubation with 1 OOµM 
homocysteine. mRNA levels of cyclin D1 and cyclin A, both stimulators of smooth muscle cell 
proliferation, were also increased. DNA synthesis in human umbilical vein endothelial cells 
however decreased in the presence of homocysteine. 
Celennajer and colleagues (1993) illustrated impaired endothelial function in the brachia! 
arteries of 9 homocystinuric children. Using high-resolution ultrasound they found decreased 
endothelium dependent flow-mediated dilation in the homocystinuric patients but not in their 
obligate heterozygote parents when compared to control subjects. Nitroglycerin mediated 
dilation, which is endothelium independent was unaffected. Reduced flow-mediated dilation 
was confinned in a group of hyperhomocysteinaemic patients compared to controls using 
identical methods. Nitroglycerin mediated dilation was as previously reported not affected 
r.:,Noo et al, 1997). Similar findings were reported in monkeys with diet induced 
hyperhomocysteinaemia. Using quantitative angiography and Doppler measurement of blood 
flow, the authors showed a significantly greater decrease in blood flow in response to intra-
arterial collagen infusion in homocysteinaemic monkeys compared to controls (Lentz et al, 
1996). 
McDonald et al (1964) reported increased platelet adhesiveness, but normal platelet counts in 
5 homocystinuric patients compared to controls. Harker and coworkers (197 4) reported 
decreased platelet survival times and a threefold increase in platelet consumption, but nonnal 
platelet counts in 4 homocystinuric patients compared to controls. Uhleman et al (1976) 
however, found no difference in platelet survival times or overall morphology using electron 
microscopy, in 5 homocystinuric patients compared to controls. There is evidence that 
increased homocysteine may increase platelet production of the prothrombotic thromoboxane 
A2. Platelet rich plasma incubated in the presence of either 1 mM DL-homocysteine or L-
homocystine showed a significant increase in the production of thromboxane 82, the stable 
metabolic end product of thromboxane A2. This increase was not observed in the presence 
of methionine, cysteine or cystine (Graeber et al, 1982). Di Minno et al (1993) could not 
confinn these findings in vitro, but did find increased urinary excretion of 
11-dehydrothromboxane 82, a major metabolic derivative of thromboxane 82 in 11 
homocystinuric patients compared to controls. 
The influence of homocysteine on various components of the clotting cascade has also been 
investigated. Rodgers and Kane (1986) illustrated increased factor V activity in cultured 
endothelial cells treated with homocysteine, which lead to increased activation of prothrombin 
to thrombin by the Factor Va:Xa complex. Rodgers and Conn (1990) later illustrated that the 
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increased factor V activation was due to decreased activation of protein C by the direct 
inhibition of thrombin, reducing its ability to inactivate factor Va. Lentz and Sadler (1991) 
however, showed that the inhibition of protein C activation by thrombin appears to effected by 
diminished levels of thrombomodulin, which acts as a cofactor in this activation. Decreased 
thrombomodulin levels appear to be due to inhibition of the post-translational modification and 
transport of the protein along the secretory pathway. Their findings have been supported by 
Hayashi et al (1992), who illustrated a negative correlation between the cofactor activity and 
thrombin binding ability of thrombomodulin and homocysteine concentration. Antithrombin 
appears to be another component affected by increased homocysteine. Antithrombin levels 
in seven homocystinuric patients were shown to be about 50% of the control levels (Giannini 
et al, 1975). Decreased antithrombin Ill activity in homocystinuric patients has also been 
reported by Palareti and Coccheri (1989) and Brattstrom et al (1989). All of the factors 
discussed above eventually lead to a more thrombotic environment. 
Mild hyperhomocysteinaemia and vascular disease 
In 1969, McCully postulated that homocysteine was responsible for the precocious vascular 
damage he observed in autopsy material obtained from a homocystinuric patient with 
deficient cobalamin metabolism. A great deal of work since then has focused on the 
association between elevated serum homocysteine and the development of vascular disease. 
Wilcken and Wilcken (1976) measured homocysteine after methionine load in a group of 25 
patients with angiographically proven coronary artery disease compared to a healthy control 
group. A significantly higher number of patients showed raised post methionine load levels of 
homocysteine compared to the control group. Boers et al (1985) investigated 75 young 
patients with vascular disease and confirmed hyperhomocysteinaemia due to CBS deficiency 
in 7/25 patients with peripheral vascular disease, 7/25 patients with cerebrovascular disease 
and 0/25 patients with myocardial infarction. Clarke et al (1991) illustrated 
hyperhomocysteinaemia in 16/38 patients with cerebrovascular disease, in 7/25 patients with 
peripheral vascular disease and in contrast to Boers, in 18/60 patients with coronary artery 
disease. CBS deficiency was identified in 18/23 hyperhomocysteinaemic patients who 
suffered from vascular disease. A recent study by Den Heijer et al (1996) of 269 patients with 
clinically confirmed deep-vein thrombosis showed that subjects with fasting plasma 
homocysteine >22µM had an odds ratio of 4:1 to suffer from deep-vein thrombosis and that 
plasma homocysteine levels had to reach a certain threshold before exerting a thrombogenic 
effect. 
A European study consisting of 750 patients with atherosclerosis and 800 controls illustrated 
that the relative risk for the development of vascular disease was 2.2 for subjects with plasma 
homocysteine in the top quintile of the distribution. This study also investigated other risk 
factors and found that homocysteine was an independent risk factor for the development of 
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vascular disease and that plasma homocysteine levels have a graded dose dependant effect 
on the risk. An additional 27% of the subjects were identified as suffering from 
hyperhomocysteinaemia by methionine load (Graham et al, 1997). A meta-analysis of 27 
studies investigating the link between plasma homocysteine and vascular disease, 
consistently showed that homocysteine is an independent risk factor for the development of 
vascular disease, even when using different methods and studying different populations 
(Boushey et al, 1995). The results obtained by the case-control studies have been supported 
by prospective studies, which record the incidence of vascular disease after an initial 
homocysteine measurement. The most notable of these, a study of 14916 US physicians, 
showed that the homocysteine levels in the subjects who did develop heart disease was 
significantly higher than in controls. The relative risk for vascular disease for subjects with 
plasma homocysteine in the highest 5% of the range was 3.4 after correcting for the standard 
risk factors (Stampfer, 1992). 
The incidence of vascular disease in obligate heterozygotes for CBS deficiency has also been 
investigated. High-resolution ultrasound has been employed as a non-invasive method of 
assessing vascular damage. Celemajer et al (1993) found impaired flow-mediated dilation in 
the brachia! arteries of homocystinuric patients compared to controls, but not in their obligate 
heterozygote parents. Rubba et al (1990), however, using similar techniques reported a 
higher incidence of arterial wall damage and stenoses in obligate heterozygotes for CBS 
deficiency compared to control subjects. The thermolabile variant of MTHFR has been 
illustrated to occur with a high frequency in the general population and to be a cause of mild 
hyperhomocysteinaemia. A recent analysis of 23 case control studies however, could not 
confirm any association of this variant with an increased risk for the development of vascular 
disease (Brattstrom et al, 1998). Increased risk for vascular disease has also been ascribed 
to decreased plasma vitamin B6 and folate levels. Verhoef et al (1996) measured lower 
plasma vitamin B6 and folate, but not vitamin B12 in patients who had suffered from 
myocardial infarction compared to controls. This finding has been confirmed by a European 
multi-center case control study consisting of 750 patients with vascular disease and 800 
control subjects. They illustrated that plasma folate levels below the first decile and plasma 
vitamin B6 levels below the second decile were associated with increased risk for the 
development of vascular disease in the control subjects and that this was independent of 
plasma homocysteine in the case of vitamin B6 (Robinson et al, 1998). 
l-1-
The scope of this study 
The aim of the work presented here was to investigate the contribution of CBS deficiency to 
hyperhomocysteinaemia in patients suffering from PVD without any of the conventional risk 
factors for the development of PVD. CBS deficiency was investigated as a cause of 
hyperhomocysteinaemia as it is the most common cause of the homocystinuria the 
homozygous and severe form of the disease. The specific objectives of this study were: 
1. To standardise the CBS assay, and to investigate factors influencing CBS activity as 
measured in lysates of cultured fibroblast cells. The extent to which each of the different 
factors affect the measured CBS activity was also determined. This aspect was 
especially important, as the activity had been shown to be highly variable from one 
occasion to the next. This study aimed to compare enzyme activity between a control 
group and a group of patients with hyperhomocysteinaemia. Such a comparison would 
be difficult if the enzyme assay were not reproducible. Additionally, the ranges of CBS 
activity measured in control subjects and patients known to be heterozygous for CBS 
deficiency has been shown to overtap significantly by several researchers. The kinetic 
constants of the enzyme in the crude lysate were also determined to establish conditions 
under which maximal activity could be obtained. Assay under conditions of maximal 
activity was compared to assay under conditions of sub-maximal activity to determine the 
most effective conditions to distinguish control subjects and subjects heterozygous for 
CBS deficiency. 
2. To measure the CBS activity in the group of hyperhomocysteinaemic patients suffering 
from PVD compared to an age and sex matched control group as well as known 
homozygotes and heterozygotes for CBS deficiency. The aim of this section was to 
determine the contribution of CBS deficiency to the hyperhomocysteinaemia observed in 
the PVD patients. A control group as well as known heterozygotes and homozygotes for 
CBS deficiency were assayed in conjunction with PVD group as a basis for comparison. 
An additional patient who exhibited a classical homozygous CBS deficiency phenotype 
and her mother were also investigated. 
3. To confirm CBS deficiency in patients with reduced enzyme activity by employing 
molecular genetic methods to identify the genetic mutations in the coding sequence of the 
CBS gene. Messenger RNA was extracted from fibroblast cultures of the subjects and 
reversed transcribed to cDNA. The cDNA was used as a template for two rounds of 
nested PCR with two primer pairs. The PCR products were then sequenced directly 
using internal primers or ligated into pGEM-T vectors and used to transform competent 
E.coli. Insert containing plasmids were isolated and sequenced using primers to the 
15 
plasmid sequence. Where possible, base changes were confirmed by restriction enzyme 
digest of PCR products of cDNA and insert containing plasmids. 
4. Preliminary investigations into the use of two differentially radiolabelled isotopes of 
methionine to study flux through the transsulfuration and remethylation pathways were 
performed. Confluent cultured fibroblast were incubated in different media with 
L-[methyl-3H]-methionine and L-[3
5S]-methionine and the uptake and incorporation of the 
labels into acid precipitable material determined. The amount of each label associated 
with the medium and the acid soluble intracellular fraction was also determined. These 
studies were undertaken in an attempt to find a new and perhaps more reliable method to 
identify heterozygotes for CBS deficiency and to investigate the flux through and products 
of methionine metabolism. 
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MATERIALS 
L-[3-14C]-serine was purchased from Amersham Life Science (Buckinghamshire, England). 
Ampicillin, Avian Maloney virus (AMV) reverse transcriptase, dithiothreitol, and NADH were 
obtained from Boehringer Mannheim (Germany). Fast-Link DNA Ligation kit was purchased 
from Epicentre Technologies (Madison, WI 53713, USA). Thermus aquaticus polymerase 
(Taq) was obtained from Gibco Life Technologies (Paisley, Scotland). L-[35S]-methionine and 
L-[methyl-3H]-methionine was purchased from NEN Life Science Products, Inc. (Boston, MA 
02118, USA). RNase Inhibitor, Wizard Plus SV Minipreps and pGEM-T Vector were obtained 
from Promega (Madison, WI 53711-5399, USA). Qiaex II gel extraction kit was obtained from 
Qiagen (Santa Clarita, CA 91355, USA). Diethyl pyrocarbonate, homocysteine-S-thiolactone, 
propargylglycine, pyridoxal-5-phosphate, pyruvate, S-adenosyl methionine and 20x20cm 
cellulose TLC plates were obtained from Sigma-Aldrich (St. Louis, MO 63178, USA). Fetal 
calf serum (FCS) was obtained from Highveld Biological Supplies (Kelvin, South Africa). 
Dulbecco's modification of Eagle's minimal medium (DMEM) was obtained from Gibco Life 
Technologies (Paisley, Scotland) and BioWhitaker (Walkersville, Maryland 21793, USA). 
Diethyl pyrocarbonate (DEPC) treated water was made up by adding 200µ1 DEPC to 100ml 
water, mixing well, incubating at room temperature for 15 minutes and autoclaving for 30 
minutes. 
LB medium contained 1 Og/L tryptone, 5g/L yeast extract and 10g/L NaCl. The medium was 
adjusted to pH 7 with SM NaOH and was autoclaved. Solid media contained an additional 
15g/L of Agar. Selective media contained an additional 1 OOµg/L Ampicillin, added after the 
media had been autoclaved and had cooled down to -50°C. For the purpose of blue/white 
screening, agar plates were coated with 40µ1 of a 10:1 mixture of 20mg/ml Xgal in dimethyl 
formamide and 1 OOmM IPTG in sterile distilled water, both stored at -20°C. 
Medium Z contained 130mM NaCl, 5mM KCI, 1 mM CaC'2, 1 mM MgCl2 , 1 SmM Hepes and 
4mg/L phenol red. 
Solution D consisted of 4M guanidinium thiocyanate, 25mM sodium citrate pH 7, 0.5% 
sarcosyl and 1 OOmM 2-mercaptoethanol. A stock solution that is stable at room temperature 
for three months was prepared by adding 58.6ml water, 3.5ml 750mM sodium citrate pH 7, 
and 5.3ml 10% sarcosyl to 50g guanidinium thiocyanate in the manufacturer's bottle. To 
obtain a working solution 72µ1 2-mercaptoethanol was added to 10ml stock solution. 
\J'-Broth contained 20g/L tryptone, 5g/L yeast extract, 20mM Mg2S04 , 1 OmM NaCl and SmM 
KCI and was autoclaved. Transformation buffer I (TFBI) contained 30mM potassium acetate, 
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1 OOmM RbC'2, 1 OmM CaCl2, SOmM MnC'2 and 15% glycerol. The buffer was adjusted to pH 
5.8 with 0.2M acetic acid and filter sterilized. Transformation buffer II (TFBII) contained 
1 OmM MOPS, 75mM CaCl2 , 1 OmM RbC'2 and 15% glycerol. The buffer was adjusted to pH 
6.8 with 0.1 M HCI and filter sterilized. 
2xTY medium contained 16g/L tryptone, 10g/L yeast extract and Sg/L NaCl and was 
autoclaved. 
Glucose/Tris/EDTA (GTE) contained SOmM glucose, 25mM Tris, pH 8.0 and 10mM EDTA, 
was autoclaved and stored refrigerated. SM potassium acetate solution was made up by 
adding KOH to 29.5ml glacial acetic acid until the solution reached pH 4.8 and the volume 
made up to 100ml with distilled de-ionized water. 
Tris/EDTA (TE) contained 25mM Tris, pH 8.0 and 10mM EDTA and was autoclaved. 
Primers 
The following primers were used to amplify sections of the cystathionine beta-synthase cDNA 
or in sequencing reactions. The primers are numbered according to the human CBS cDNA 
sequence, starting with position 1 at the ATG translation start site (Kraus et al, 1993). The 
letter "f' indicates a forward primer while "r" indicates a reverse primer. The length as well as 
the theoretical melting temperature of each primer is also given. 
Primer Sequence Length (bp) T m(°C} 
CBSf-107 5' -GACCACAAGGCTACGACAAAA TGA-3' 24 54 
CBS f-57 5'-GTGGCGAGTTTGAGACA TTCCTCTG-3' 25 55 
CBS f186 5'-GTCCCCACATCACCACACTGC-3' 21 55 
CBS f382 5'-GAGGATGCTGAGCGCGAC-3' 18 51 
CBS f570 5'-GACGCCCACCAA TGCCAGG-3' 19 58 
CBS f665 5' -AACGACCGCAACGCCATCA-3' 19 55 
CBS f769 5'-ACGGGCGGCACCATCACG-3' 18 60 
CBS f1106 5' -GCTGCGTGGTCA TTCTGCCCG-3' 21 62 
CBS f1295 5' -GGCACACCATCGAGATCCTCC-3' 21 55 
CBS f1487 5' -TGGGCAGGCTCTCGCACATCC-3' 21 62 
CBS r1212 5' -TTCTTCGGGACCCACCACCG-3' 19 54 
CBS r1928 5'-CATCCT ACTTGTGTCCGTT ACTGC-3' 25 56 
CBS r1955 5'-CGTCTCACCT AA TTTCCGTTTTCTCT-3' 26 54 
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Patients 
Twelve patients suffering from peripheral vascular disease (patients 972 to 977, 979 to 983 
and 1000) were selected. The group consisted of non-diabetic, non-smokers to whom no 
known clinical reason for their condition could be ascribed. The group of 9 males and 3 
females were aged between 32 and 60 years (average age 42.5 ± 7.4) and were of varied 
ethnic origin. A complete list of the patients' information is given in table 1 in Results. Patient 
960 is an 11-year old, homocystinuric female and her mother, patient 961 showed no clinical 
abnormalities. Two siblings who share the same compound heterozygote phenotype for CBS 
deficiency, patients 488 and 489 along with patient 960 where used as a reference for 
homozygous CBS deficiency. Their confirmed heterozygote parents where used along with 
patient 961 as a reference for heterozygous CBS deficiency. 
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METHODS 
Plasma homocysteine measurement 
Plasma homocysteine concentrations were determined in our laboratory as part of a routine 
service using a method adapted from Brattstrom et al (1988). Subjects were screened by 
measuring plasma homocysteine in the fasting state, as well as six hours after an oral 
methionine load of.1 mg per kg of bodyweight. Methionine was taken orally dissolved in 
orange juice and subjects were fed a diet free from protein for the six hour period. EDTA 
venous blood samples were obtained from the subjects and separated by centrifugation, 
within one hour of collection and stored frozen until assay. Disulfide bonds were reduced by 
adding 25µ1 1 M OTT to 500µ1 plasma and incubating at 37°C for 1 h. Norleucine was added 
as an internal standard. Protein was denatured with 100µ1 50% SSA, centrifuged and de-
proteinized plasma filtered through a 0.22µ filter. Samples were separated on a Beckman 
System 6300 amino acid analyzer using a cation-exchange column with lithium citrate buffers 
of increasing pH. Amino acids were detected spectrophotometrically by post-column 
ninhydrin derivatization. Homocysteine was quantified by measuring the height of the 
homocysteine and the norleucine internal standard peaks, as well as a known homocysteine 
standard separated during the same run. 
Tissue culture 
Human fibroblast cultures were established from skin biopsies, cut from the foreanns of the 
patients. Biopsy material was sliced into approximately 1mm
3 pieces, covered with 0.5ml 
DMEM containing 10% FCS and 30mg/ml penicillin, 50mg/ml streptomycin and 25mg/ml 
neomycin. Fragments were dispensed into several tissue culture dishes and covered with 
sterile coverslips. An additional 2.5ml of the above mentioned medium was added to the 
dishes and the dishes subsequently incubated in an atmosphere of 10% CO2 at 37°C in a 
humidified incubator. Medium was changed twice a week. Once a reasonable amount of 
cells had grown from out from the fragments, the coverslips were turned over and placed in a 
new tissue culture dish. Both of the cultures were then grown to confluence before 
trypsinizing and transfer to a tissue culture flask. 
All cultures were maintained in DMEM containing 10% fetal calf serum, in an atmosphere of 
10% CO2 at 37°C and omitting antibiotics. This results in avoidance of infections by enforcing 
a high standard of aseptic technique, and is highly valuable in guarding against mycoplasma 
infection. Cultures were fed twice a week by replacing the culture medium using the standard 
precautions to maintain sterility (Freshney, 1994). Cells were periodically examined for the 
presence of mycoplasma infection (Chen, 1977). Once fibroblast cultures had reached 
confluence, they were trypsinized and subcultered. Fibroblast culture monolayers were 
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released by treating with trypsin solution (0.25% trypsin, 1mM EDTA in sterile distilled water) 
for 5 to 1 O minutes at 37°C. A quarter of the original culture was reseeded into the same 
flask. For the purposes of enzyme assays, the remaining three quarters of the trypsin 
suspension was cooled on ice and washed once with ice cold complete medium to inhibit 
trypsin activity and twice with ice cold PBS. Cells were sedimented for 5 minutes at 1 OOOrpm 
in a Sigma 3E-1 bench-top centrifuge. 
Cell lysis 
Trypsinized, washed fibroblast suspensions were lysed using three methods: sonication using 
a Branson sonicator, freezing and thawing in a dry ice and ethanol mixture and treatment with 
Digitonin (Mackall et al, 1979). The protein concentrations of the extracts were determined 
using the Bio-Rad method (Bradford, 1976) with bovine serum albumin as a standard. 
Digitonin treatment 
The trypsinized, washed cell pellets were re-suspended in 100µ1 Digitonin solution (3mg/ml 
Digitonin, 250mM sucrose and 3mM EDTA in sterile distilled water, freshly prepared) and 
incubated at 4°C for 5 minutes. Cell debris was sedimented by centrifugation at 1 OOOOrpm in 
a Sigma 2MK Eppendorf centrifuge at 4°C. The supernatant containing the material released 
from the cells was transferred to a clean Eppendorf tube and kept at 4°C until use. 
Sonication 
The trypsinized, washed cell pellets were re-suspended in 100µ1 PBS and sonicated, on ice 
with a Branson sonicator, for 10 cycles and 10% of the duty cycle at 10% of the maximal 
output. Cell debris was sedimented by centrifugation at 1 OOOOrpm in a Sigma 2MK 
Eppendorf centrifuge at 4°C. The supernatant containing the material released from the cells 
was transferred to a clean Eppendorf tube and kept at 4°C until use. 
Freezing and thawing 
The trypsinized, washed cell pellets were re-suspended in 100µ1 PBS and frozen in dry ice 
ethanol and thawed in a water bath at 37°C successively six times. Cell debris was 
sedimented by centrifugation at 1 OOOOrpm in a Sigma 2MK Eppendorf centrifuge at 4°C. The 
supernatant containing the material released from the cells was transferred to a clean 
Eppendorf tube and kept at 4°C until use. 
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Lactate dehydrogenase assay 
Cell lysates were assayed for lactate dehydrogenase activity by measuring the conversion of 
NADH to NAO+ (decrease in absorbance at 340nm) as a result of the reduction of pyruvate to 
lactate (Pesce et al, 1964). The reaction mixture contained 1.6mM pyruvate, 0.175mM NADH 
and 1 OOmM NaH2P04 pH 6.8, in a volume of 1 ml at 37°C in a quartz cuvet. To this mixture, 
5µ1 of the lysate was added and the contents mixed by inversion. The cuvet was placed in a 
thermocell at 37°C in a Beckman DU-62 spectrophotometer and the absorbance at 340 nm 
measured at 20 second intervals for three minutes. The slope of the absorbance as a 
function of time was used to calculate the reaction rate. 
Citrate synthase assay 
Citrate synthase activity in cell lysates was measured by the production of citrate from acetyl-
CoA and oxaloacetate. Dithionitrobenzoate was used as a chromogenic indicator of citrate 
production (Lowenstein, 1969). Included in the reaction mixture, in a volume of 1ml was 
300µM acetyl-CoA, SOOµM oxaloacetate, 1 OOµM dithionitrobenzoate, SOmM Tris, pH 8.1. 
Acetyl-CoA and dithionitrobenzoate were mixed and allowed to equilibrate at 25°C for 1 
minute. Fifty microlitres of the cell lysate was added and the reaction mixture incubated at 
25°C for 3 minutes to allow residual oxaloacetate in the lysate to be utilized. The absorbance 
of the mixture was measured at 412nm to obtain the starting value. Subsequently 
oxaloacetate was added and the absorbance at 412nm measured after three minutes to 
obtain the final value. The reaction rate was calculated from the difference between the final 
and initial absorbance values. 
Cystathionine beta-synthase assay 
Cystathionine J3-synthase irreversibly condenses homocysteine and serine to produce 
cystathionine. The assay for enzyme activity is based on the conversion of 
14C-[3]-serine to 
14C-cystathionine in lysates of fibroblast and lymphoblast cell lines derived from patients and 
control subjects. Reaction products are separated by chromatographic methods and the 
radioactive cystathionine quantified as a measure of the enzyme activity. One unit of enzyme 
activity is defined as the amount of enzyme that catalyses the formation of 1 nanomole of 
cystathionine per hour. Results are expressed as units of activity per milligram of protein 
measured in the lysate. 
Homocysteine preparation 
Homocysteine was prepared by incubating 7.7mg homocysteine-S-thiolactone in 100µ1 SM 
NaOH at 37°C for 5 minutes. The pH was adjusted to 8.6 with -220µ1 2M HCI and 50µ1 
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100mM Tris pH 8.6. Dithiothreitol was added to a final concentration of 20mM and the 
volume made up to 500µ1 with distilled water. 
Measurement of cystathionine beta-synthase activity 
CBS was essentially assayed under two sets of conditions. Under conditions of maximal 
enzyme activity, the reaction mixture contained 20mM L-homocysteine (freshly prepared from 
its thiolactone form), 40mM L-serine, 14C-serine to a known specific activity, 2mM pyridoxal-5-
phosphate, 1 mM S-adenosyl methionine, 1 mM propargylglycine, 1 OOmM Tris pH 8.6 and 0.05 
to 0.10mg cell protein. The conditions of sub-maximal enzyme activity were essentially based 
on Fowler et al, (1978) and the reaction mixture usually consisted of 10mM L-homocysteine 
(freshly prepared from its thiolactone form), 5mM L-serine, 
14C-serine to a known specific 
activity, 1 OOmM Tris pH 8.6 and 0.05 to 0.10mg cell protein. Assay conditions are specified 
where they differed from the above. The reaction was initiated by the addition of the cell 
extract and incubated at 37°C for 4 hours. The reaction was terminated by precipitating 
protein by the addition of 10µ1 12.5% sulphosalicylic acid. Precipitated protein components 
were sedimented by centrifugation in an Eppendorf centrifuge for 1 O minutes and the 
supernatant transferred to a clean Eppendorf tube. The solution was adjusted to pH 2 with 
the addition of 2µ1 2.5M NaOH. 
Separation of the reaction mixture was achieved using a Beckman System 6300 amino acid 
analyzer coupled to a Gilson FC-203 fraction collector. The amino acid analyzer was set up 
to run a standard program for the separation of total amino acids, using a cation-exchange 
column with lithium citrate buffers of increasing pH. The fractions containing cystathionine 
were collected in scintillation vials, dissolved in 10ml Packard Hionic-Fluor scintillation fluid 
and counted in a Beckman LS60001C liquid scintillation counter using an open window. An 
aliquot of original reaction mixture was also counted to determine the specific activity of the 
serine. 
Alternatively the reaction mixture was separated using cellulose thin layer chromatography. 
Aliquots of the reaction mixture were spotted on cellulose TLC plates and resolved for 48 to 
72 hours in a mixture of 2-propanol/acetic acid/water (80/6/20). An aliquot of the original 
reaction mixture was applied to the resolved and dried TLC plates to determine the specific 




RNA was isolated using the acid guanidinium thiocyanate-phenol-chlorofonn method of 
Chomczynski and Sacchi (1987). Lymphoblast cultures were centrifuged at 1 OOOrpm for 5 
minutes in a Sigma 3E-1 centrifuge. Cells were washed twice with sterile saline. One ml 
solution D was added to the cell pellet, the suspension mixed by inversion and transferred to 
a clean 8ml polypropylene tube. Sequentially 0.1 ml 2M sodium acetate, pH 4, 1 ml water 
saturated phenol and 0.2ml chlorofonn/isoamyl alcohol (49/1) was added to the tubes. Tubes 
were mixed by inversion after each addition and vigorously mixed for 15 seconds after the 
final step. The mixture was incubated on ice for 15 minutes. 
Fibroblast cultures were washed by rinsing tissue culture flasks twice with saline. One ml 
solution D was added directly to the flasks and incubated on ice for 15 minutes. A rubber 
policeman was used to detach cells from the inside surface of the flask and the contents 
transferred to a clean 8ml polypropylene tube. The remaining reagents were added exactly 
as for lymphoblasts and the tubes incubated for a further 5 minutes after the final step. 
Tubes were centrifuged at 10000g for 15 minutes at 4°C in a Heraeus Sepatech Varifuge 
20RS. The aqueous phase containing the RNA was transferred to a fresh tube and the DNA 
and protein contained in the interface and organic phase discarded. RNA was precipitated by 
incubating in 1 volume of isopropanol at -80°C for 1 hour, followed by a 20 minute 
centrifugation step at 10000g and 4°C. The pellet was dissolved in 0.3ml solution D, 
transferred to a clean Eppendorf tube and RNA precipitated in 1 volume isopropanol at -80°C 
for 1 hour. Tubes were centrifuged in an Eppendorf centrifuge at 4°C to sediment RNA. 
Supernatant was discarded and the RNA pellet washed three times with 75% ethanol (made 
up with DEPC treated water). Finally RNA was dried under vacuum and dissolved in 100µ1 
DEPC treated water. The quality of the RNA preparation was assessed by calculating the 
ratio of absorbance at 260nm to 280nm. The nucleic acid concentration was determined from 
the absorbance at 260nm. 
First strand cDNA synthesis 
cDNA was reverse transcribed from the extracted total RNA using Avian Maloney virus 
(AMV) reverse transcriptase and an oligo dT primer to the 3' polyadenosine tail of the 
message. Included in the reaction mixture was 1 to Sµg total RNA, Sµg oligo dT primer, 
dNTP's at O.SmM each, BOU AMV reverse transcriptase, SU RNase inhibitor, 1 x 
manufacturer's buffer and sterile distilled water to 100µ1. To ensure effective priming of the 
mRNA template, oligo dT, mRNA and water was combined, heated to 65°C for 5 minutes and 
then cooled on ice. The remaining components of the reaction were subsequently added and 
the reaction allowed to proceed at 42°C for 1 hour. 
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Polymerase chain reaction (PCR) 
PCR amplification of cDNA was performed using a Techne PHC-2 thermocycler. The PCR 
reaction mixture contained the following components: forward and reverse primers at 0.5µM 
each, dNTP's at 200µM each, 1 to 4mM MgCl2, 1 x manufacturer's buffer, 25mU/µI Thermus 
aquaticus (Taq) polymerase, 1-5µ1 of the cDNA template and sterile distilled water to a total 
volume of either 50 or 100µ1. Eighty microlitres of mineral oil was layered on top of the 
reaction mixture to prevent evaporation. 
Amplification of cystathionine beta-synthase cDNA 
For the purpose of direct sequencing the CBS cDNA was amplified in two over1apping 
segments of about 1 OOObp each. A semi-nested approach using three primers in two rounds 
of amplification was followed in both cases. The 5' section was amplified using the primers 
CBS f-107 and CBS r1212 for 40 cycles in the initial round of amplification. The PCR 
products from the initial amplification was subsequently further amplified using CBS f-57 and 
CBS r1212 for 30 cycles in a second round of amplification. The temperature profile 
consisted of denaturing at 94°C for 45s, annealing at 50°C for 45s and extension at 72°C. 
Extension time was increased in a stepwise manner and was 120s during the first thirteen 
cycles, 150s during the middle thirteen cycles and 180s during the last thirteen cycles in the 
first round of amplification. During the second round of amplification the extension time was 
increased in a similar fashion every ten cycles. The 3' section of the CBS cDNA was 
amplified in a similar fashion using the primers CBS f1106, r1955 and r1928 and an annealing 
temperature of 54°C. The reactions took place in 2mM MgC12. In all cases 1 µI of the first 
PCR reaction was used as template for the semi-nested PCR. A reaction excluding the 
template DNA was used in both rounds of amplification to detect the possible erroneous 
amplification of contaminating template. 
For the purpose of cloning, a -2000 base pair segment of the CBS cDNA, spanning the entire 
coding region, was amplified. A nested approach was again utilized. The primers CBS f-107 
and CBS r1955 were used for 40 cycles in the initial round of amplification. The PCR 
products from the initial amplification was subsequently further amplified using CBS f-57 and 
CBS r1928 for 30 cycles in a second round of amplification. The temperature profile 
consisted of denaturing at 94°C for 45s, annealing at 54°C for 45s and extension at 72°C. 
Extension time was increased in a stepwise manner and was 120s during the first thirteen 
cycles, 180s during the middle thirteen cycles and 240s during the last thirteen cycles in the 
first round of amplification. During the second round of amplification the extension time was 
increased in a similar fashion every ten cycles. The optimal MgCl2 concentration was 
determined to be 1.5mM. Gel purification was again employed to clean the PCR products. 
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Gel purification of PCR products 
Products from four identical 100µ1 PCR reactions of each template were pooled and mineral 
oil removed by organic extraction with 1 volume of chloroform. The organic and aqueous 
phases were separated by centrifugation in an Eppendorf centrifuge for 1 minute. The top 
aqueous layer was transferred to a clean Eppendorf tube and DNA precipitated by adding 
1/10 volume 3M sodium acetate, pH 5.2 and 2 volumes of ethanol. This was mixed well and 
incubated at -80°C for 15 minutes. DNA was sedimented by centrifugation in an Eppendorf 
centrifuge for 10 minutes, the supernatant removed and DNA washed by adding 1 ml of 70% 
ethanol. Tubes were centrifuged in an Eppendorf centrifuge for 1 minute, supernatant 
discarded and DNA dried under vacuum. DNA was dissolved in 20µ1 sterile distilled water. 
The pooled and concentrated PCR product was resolved using agarose gel (1.5 to 2%) 
electrophoresis. The appropriate bands were excised from the gel using a scalpel blade and 
transferred to a clean Eppendorf tube, taking care to minimize exposure of the DNA to 
ultraviolet light. DNA was extracted from the agarose gel using the Qiaex II gel (Qiagen) 
extraction kit following the manufacturer's protocol. DNA was recovered in sterile distilled 
water. 
Cloning of CBS cDNA 
Purified CBS PCR products were ligated into the plasmid cloning vector pGEM-T. Ligation 
into this vector is based on the terminal transferase activity of Taq polymerase, which adds a 
single 3' overhanging adenine to the PCR product. The vector is supplied as a linear 
molecule with single 5'-overhanging thymidines, which are complimentary to the 3' single 
adenines in the PCR product. This feature facilitates the direct ligation of PCR products into 
this vector without any further manipulations. The multiple cloning site occurs within the 
coding region of the /acZ gene, coding for the enzyme ji-galactosidase. Successful ligation of 
the insert into the vector leads to inactivation of the JacZ gene, providing a marker for the 
detection of colonies containing recombinant vectors. This is achieved using solid media 
containing IPTG, which acts as an inducer for the transcription of the /acZ gene and Xgal, a 
synthetic, colourless substrate of [1-galactosidase yielding a blue product. The vector also 
contains an Ampicillin resistance gene allowing for the selection of transformed bacteria using 
antibiotic containing media. 
Ligation of CBS cDNA into pGEM-T 
Ligation of purified PCR products into the plasmid vector was carried out according to the 
manufacturer's protocol for T-vectors. The reaction mixture contained 200ng plasmid DNA, 
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song PCR product (2:5 molar ratio of plasmid to insert), 1 x manufacturer's ligation buffer, 
O.SmM ATP and 2U of DNA ligase in a final volume of 15µ1. Ligation was allowed to proceed 
in a water bath at 16°C for 1 hour and ligase was inactivated by heating to 70°C for 15 
minutes. 
Preparation of competent cells using RbC/2 
Competent E.coli cultures were prepared by RbCl2 treatment (Ausubel et al, 1995). Frozen 
glycerol stocks of a commercial strain of E.coli, XL 1 Blue, were streaked onto LB plates and 
allowed to grow overnight at 37°C. A single colony was selected from the plate and used to 
inoculate 40ml '¥-broth and grown overnight at 37°C, with shaking. Two pre-warmed 200ml 
volumes of '¥-broth were each inoculated with 4ml of the overnight culture and grown with 
agitation at 37°C until the cell suspension reached an absorbance of between 0.5 and 0.6 at 
600nm. Flasks were cooled on ice and the bacteria sedimented at 4°C at 5000g for 10 
minutes in pre-chilled centrifugation tubes. Cell pellets were re-suspended in 40ml of ice-cold 
TFBI and incubated on ice for 30 minutes. Bacteria were again sedimented at 4°C at 5000g 
for 1 O minutes, re-suspended in 8ml of ice-cold TFBII and incubated on ice for 15 minutes. 
The cell suspensions were aliquoted into 250µ1 volumes using chilled pipette tips, frozen in 
liquid nitrogen and stored at -70°C. Transformation efficiency was assayed using 1 ng of 
pUC18 plasmid vector. 
Transformation 
Ligated plasmid vectors were used to transform the RbCl2 competent XL 1 Blue E.coli strain. 
Aliquots of the competent cells were thawed on ice and distributed into 50µ1 volumes in 
Eppendorf tubes. One µI of each ligation mixture was added to the competent cell 
suspension and incubated at 4°C for 45 minutes. The suspensions were subsequently 
exposed to a heat shock at 37°C for 30 seconds to allow for the entry of the plasmid vectors 
into the bacteria, and transferred to 1ml ice cold 2xTY medium. Bacterial cells were 
stimulated to recover by incubating cultures with shaking at 37°C for 1 hour. Cultures were 
centrifuged in an Eppendorf centrifuge for 30 seconds, resuspended in 100µ1 of 2x TY 
medium and two equal volumes plated onto Ampicillin containing LB agar plates coated with 
Xgal an IPTG. The plates were incubated overnight at 37°C. White colonies, carrying insert 
containing vector, as well as blue colonies, containing self-ligated vector, were streaked onto 
a fresh Ampicillin containing LB agar plate and grown overnight at 37°C. 
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Mini preps 
The alkaline lysis method of preparing plasmid DNA was performed using either the method 
of Birnboim and Doly (1979) or a commercial Wizard Plus SV miniprep kit. In these 
procedures, bacteria are lysed in the presence of sodium dodecyl sulfate and NaOH, which 
denature bacterial proteins and chromosomal and plasmid DNA respectively. Upon the 
addition of potassium acetate the mixture is neutralized, resulting in the rapid re-annealing of 
plasmid DNA. SOS, bacterial proteins and chromosomal DNA precipitate and can be 
removed by centrifugation. 
A single colony from each plate was grown overnight in 5ml Ampicillin containing LB medium 
with shaking at 37°C. Bacterial cells were sedimented by successive centrifugation in an 
Eppendorf centrifuge. The pellets were re-suspended completely in 100µ1 GTE by vortexing 
and subsequently incubated at room temperature for 5 minutes. Bacterial cells were lysed 
and DNA and protein denatured by adding 200µ1 of a freshly prepared solution containing 1 % 
SOS and 0.2M NaOH to the cell suspension, mixing by inversion and incubating, on ice, for 5 
minutes. The solution was neutralized with 150µ1 SM potassium acetate, pH 4.8, vortexed for 
5 seconds and centrifuged in an Eppendorf centrifuge for 3 minutes. The supernatants were 
transferred to fresh tubes, RNase A added to SOµg/ml and the solutions incubated at room 
temperature for 30 minutes. 
Residual protein contaminants were extracted by adding 500µ1 TE saturated 
phenol/chloroform/isoamyl alcohol (50/49/1), vortexing and centrifuging in an Eppendorf 
centrifuge for 2 minutes. The top aqueous layer was transferred to a fresh tube and any 
remaining phenol and protein contaminants extracted with 500µ1 chloroform. After 
centrifugation the aqueous phase was again transferred to a fresh tube. DNA was 
precipitated by adding 1 ml ice cold 100% ethanol, incubating at -70°C for 15 minutes and 
pelleted by centrifuging in an Eppendorf centrifuge for 5 minutes. The DNA pellets were 
rinsed with 70% ethanol, centrifuged for 1 minute, ethanol aspirated and the pellets dried 
under vacuum. Further purification was achieved using PEG precipitation at high salt 
concentration and elution in 70% ethanol. Dried DNA pellets were dissolved in 16.8µ1 de-
ionized water, 3.2 µI SM NaCl was added and the solution mixed well. Twenty µI of 13% PEG 
was added, the solutions mixed well and incubated on ice overnight. Samples were 
centrifuged in an Eppendorf centrifuge for 10 minutes, supernatants discarded and the pellets 
rinsed with 70% ethanol. Pellets were dried under vacuum and dissolved in 20µ1 de-ionized 
water. The quantity of DNA was estimated by comparing the band intensities of the samples 
to a standard on an agarose gel stained visualized with ethidium bromide. 
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The manufacturer's protocol was followed exactly when the Wizard Plus SV minipreps were 
used. In this method however, plasmid DNA was purified by binding to a silica gel matrix at 
low pH and elution with sterile distilled water. 
DNA Sequencing 
Sequencing of PCR products and cloned material was performed using three methods. 
Manual sequencing was performed using a Sequenase DNA sequencing kit (Amersham Life 
Science). Automated sequencing was performed by the Core Facility at UCT using a 
ThermoSequenase dye terminator cycle sequencing kit (Amersham Life Science) with an ABI 
373 DNA Sequencer (Perkin Elmer) and also at the Department of Biochemistry and 
Microbiology at UCT using a ThermoSequenase fluorescent labeled primer cycle sequencing 
kit (Amersham Life Science) with an ALFexpress DNA Automated Sequencer (Amersham 
Pharmacia Biotech AB). 
Manual Sequencing 
The Sequenase manual sequencing protocol is based on the Sanger dideoxy nucleotide 
sequencing method (Sanger et al, 1977). The manufacturer's protocol was followed with 
some modifications (Kraft et al, 1988). 
Double-stranded plasmid DNA was denatured by adding 2µ1 of a freshly prepared solution 
containing 2M NaOH and 2mM EDTA to 20µ1 of the purified mini-preps, containing 3 to 5µg 
DNA, and incubating for 5 minutes at room temperature. Intra-strand secondary structure 
formation was promoted by sequentially adding, on ice, 8µ1 1 M Tris, pH 4.5 and 3µ1 3M 
sodium acetate and DNA precipitated by adding 75µ1 ice cold 100% ethanol and incubating at 
-70°C for 30 minutes. DNA was sedimented by centrifugation in an Eppendorf centrifuge for 
5 minutes at 4°C and the pellets were washed with 200µ1 ice cold 70% ethanol. Tubes were 
centrifuged in an Eppendorf centrifuge for 2 minutes at 4°C and the pellets dried under 
vacuum after the supernatant was aspirated. The appropriate sequencing primer was 
annealed to the single stranded template by dissolving the dried DNA pellets in 7µ1 sterile de-
ionized water and 2µ1 5x Sequenase Sequencing Buffer (200mM Tris, pH 7.5, 100mM MgCh, 
250mM NaCl), adding 0.5pmol primer and incubating at 37°C for 30 minutes. The primed 
templates were subsequently centrifuged and chilled on ice. Extension and labeling of the 
complementary strand was achieved by adding 1 µI 0.1 M DTT, 2µ1 diluted Labeling Mix 
(7.5µM each of dGTP, dCTP and dTTP), 5µCi [a.-
35S)-dATP and 2µ1 diluted Sequenase 
Polymerase and incubating at room temperature for 3 minutes. The reactions were 
terminated by adding the respective dideoxy nucleotides. Three and a half µI of the reaction 
mixture was added to tubes containing 2.5µ1 pre-warmed (37°C) Termination Mixture (80µM 
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each of dATP, dGTP, dCTP and dTTP and 8µM of the specific dideoxy nucleotide) for each 
nucleotide and incubated at 37°C for 5 minutes. Tennination reactions were stopped by 
adding 4µ1 Stop Solution (95% fonnamide, 20mM EDTA, 0.05% bromo-phenol blue and 
0.05% xylene cyanol). 
Each of the tenninated sequencing reactions was resolved at 60W on a 6% denaturing 
polyacrylamide gel. The gel contained 8M urea and was prepared in the running buffer 
containing 134mM Tris, 45mM boric acid and 2.SmM EDTA. The tenninated sequencing 
reactions were loaded three times successively, each new loading occurring after the xylene 
cyanol had been run off the gel. The resolved gel was adhered to a sheet of filter paper, 
covered with cling-wrap and dried at 80°C under vacuum. The dried gel was exposed to 
autoradiography film for 72 hours, which was subsequently developed and analyzed. 
Automated sequencing at the Core Facility at UCT 
The Core Facility at UCT perfonned automated DNA sequencing using a ThennoSequenase 
dye tenninator cycle sequencing kit with an ABI 373 DNA sequencer. The following is a brief 
description of the manufacturer's protocol used. To -1µg of DNA and -Spmol primer in a 
volume of 12µ1, 8µ1 of Sequencing Reagent Pre-mix was added. The reagent pre-mix 
contained 125mM Tris, pH9.5, SmM MgCl2, T7 DNA polymerase, Thermop/asma acidophilum 
thennostable inorganic pyrophosphatase, Nonidet P40, Tween 20, 6.25% glycerol, 1.25mM 
dlTP, 0.25mM each of dATP, dCTP, dTTP and dGTP, and uniquely dye-labeled dideoxy ATP, 
dideoxy CTP, dideoxy TTP and dideoxy GTP. The sequencing reactions were allowed to 
proceed using 30 cycles of the following temperature profile: 30s at 96°C, 15s at 45°C and 
4min at 60°C. The completed sequencing reactions were precipitated with 70µ1 SmM MgCl2 
in 70% ethanol, re-suspended in 4µ1 fonnamide loading buffer and separated on a 4.75% 
PAGE gel and each uniquely labeled dideoxy tenninator detected by its fluorescence. 
Automated sequencing at the Department of Biochemistry and Microbiology at UCT 
Automated sequencing at the Department of Biochemistry and Microbiology at UCT was 
perfonned using a ThennoSequenase fluorescent labeled primer cycle sequencing kit 
(Amersham Life Science) with an ALFexpress DNA Automated Sequencer (Amersham 
Pharmacia Biotech AB). The sequencing reaction is based on the Sanger chain tennination 
technique using 7-deaza-dGTP with dye labeled M13 -40 sequencing primer at 2pmol/µ1. 
The manufacturer's instructions were followed exactly. 
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Metabolic labeling 
The metabolism of methionine in cultured fibroblasts was investigated using two radiolabeled 
isotopes of methionine. L-[
35S]-methionine was used to follow methionine through the 
transsulfuration and remethylation pathways, while L-(methyl-
3H]-methionine was used as a 
marker for methyl transfer reactions. Figure 21 shows the metabolism of methionine with the 
metabolites that the 
35S and tritium labels can be incorporated into in yellow and blue 
respectively. The 35S radiolabel can be incorporated into protein directly as methionine or 
after being metabolized through the transsulfuration pathway, as cysteine. The tritium 
radiolabel, however is on the methyl group of methionine, and is transferred to a methylated 
acceptor, mainly nucleic acid and protein. Changes in the flux through the transsulfuration 
and remethylation pathways, such as caused by enzyme deficiencies, could therefore affect 
the ratio of tritium to 
35S incorporated into acid precipitable material. 
Confluent fibroblast cultures were incubated in pre-warmed buffer or tissue culture media 
containing the isotopes. At various time intervals culture medium was removed, protein and 
DNA precipitated with 5% trichloracetic acid (TCA) and the precipitated material dissolved in 
O.SM NaOH. The medium acid soluble and acid precipitable fractions at each time point were 
counted in a scintillation counter. A O to 200keV window was used to detect tritium (which 
includes a defined contribution from 
35S) and a 400 to 600keV window was used to detect 
only 35S. The amount of each isotope was calculated for the medium, the TCA soluble 
fraction containing all the small molecular components and the TCA precipitated 
macromolecules. 
On the day preceding each experiment fibroblast cultures were seeded into 3cm polystyrene 
tissue culture dishes at a density of 3x10
5 cells per well. This number of cells had been 
determined to yield a confluent culture the following day (Baumgarten, 1984). Fibroblast 
cultures were trypsinized and re-suspended in complete medium and washed once with 
complete medium. An aliquot of the suspension, diluted 1/100 in filtered lsoton Ill was 
enumerated in a Coulter Counter. A volume of the suspension corresponding to 3x10
5 cells 
was seeded into each dish, 1 ml of complete medium added and the dishes incubated 
overnight at 37°C and an atmosphere of 10% CO2. On the day of the experiment, cells were 
visually checked for confluence. 
The medium was aspirated and the cultures washed once with Medium Z. The time course 
was initiated by adding 1 ml preheated (37°C) incubation medium containing 
35S-methionine at 
-1 µCi and [methyl-
3H]-methionine at -10µCi. At various times a dish was processed and the 
incubation medium removed and retained. The cultures were washed twice with ice-cold 
saline and subsequently twice with ice cold 5% TCA to precipitate protein and nucleic acids. 
The first TCA wash, containing the soluble cytoplasmic constituents, was also retained. The 
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precipitated material was released from the cultures by incubating with shaking in 0.1 M NaOH 
for 10 minutes. Of each fraction, 500µ1 was dissolved in 10ml Packard Hionic Fluor, an 
alkaline resistant scintillation fluid and counted in a Beckman LS60001C liquid scintillation 
counter. The TCA fraction was adjusted to pH 10 by adding15µ1 10M NaOH, before adding 
scintillation fluid. A O to 200keV window was used to detect tritium and 
35S and a 400 to 




Plasma homocysteine measurements 
Peripheral vascular disease patients were screened by measuring fasting plasma 
homocysteine as well as 6 hours after an oral methionine load. Fasting and post methionine 
load homocysteine levels as well as the change in plasma homocysteine measured in the 
subjects of this study are shown in table 1. 
Fasting Post Increase after 
methionine 





972 39 M 16.2 39.5 23.3 
973 49 M 14.1 46.5 32.4 
974 32 M 11.0 49.0 38.0 
975 39 M 17.7 - -
976 42 M 15.1 44.2 29.1 
977 45 M 14.8 45.9 31.1 
979 37 F 10.6 54.5 43.9 
980 60 M 17.3 - -
981 47 F 19.7 52.1 32.4 
982 45 M 6.7 41.7 35.0 
983 36 F 28.2 69.0 40.8 
1000 39 M 28.0 67.9 39.9 
Table 1. Fasting plasma homocysteine and plasma homocysteine 6h after an oral methionine load. 
The increase in plasma homocysteine from the fasting level to the 6h post methionine load level is also 
shown. The upper limit of normal for each measurement established in our laboratory is given in square 
brackets and abnormally high values printed in bold italic lettering. 
Six patients in the PVD group showed fasting homocysteine levels above the upper limit of 
normal (patients 972, 975, 980, 981, 983 and 1000), two of whom were not available for 
methionine loading (patients 975 and 980). Three (patients 981, 983 and 1000) of the 
remaining four showed abnormally high post methionine load homocysteine as well as 
increase in homocysteine following the methionine load. Patient 972 showed only an 
abnormally high fasting homocysteine level. All six subjects with normal fasting homocysteine 
levels showed hyperhomocysteinaemia as ascertained by post methionine load peak or the 
increase in plasma homocysteine after loading (patients 973, 974, 976, 977, 979 and 982). 
33 
Cystathionine p-synthase activity in fibroblasts 
Method of ce/1 /ysis 
Three methods of cell lysis were investigated to determine their effectiveness in the release of 
cytoplasmic constituents from cultured fibroblasts. The aim of this investigation was to find a 
method that preferentially releases cytoplasmic components while leaving organelles intact, 
as it has been illustrated that post-translational proteolytic cleavage of CBS leads to a 60-fold 
increase in enzyme activity (Skovby et al, 1983). Release of lysosomal material may 
therefore lead to proteolytic cleavage of the enzyme and erroneously high and/or variable 
activity. 
Digitonin treatment of cultured cells has been proposed as a rapid and mild procedure for the 
preferential release of cytoplasmic constituents (Mackall et al, 1979), while freezing and 
thawing and sonication have been used more frequently as standard methods of lysis. 
Lactate dehydrogenase was used as a marker for the release of cytoplasmic components, 
while citrate synthase, occurring in the mitochondria was used as a measure of organellar 
disruption. A trypsinized control fibroblast cell line was resuspended in PBS and divided into 
three equal parts. The suspensions were lysed with digitonin, by freezing and thawing in dry 
ice/ethanol or by sonication. Lactate dehydrogenase and citrate synthase assays were 
subsequently performed on each supernatant. Both the activities were measured in the linear 









































Digitonin Sonication Freeze/thaw 
Method of lysis 
Figure 2. Lactate dehydrogenase (open bars) 
and citrate synthase (hashed bars) activity 
released from identical suspensions of a 
trypsinized fibroblast culture lysed by either 
sonication, freezing and thawing or treatment 
with digitonin. 
Figure 2 shows the absolute amount of both enzyme activities that was released by each 
method of lysis. Sonication and freeze/thawing appears to release very similar amounts of 
lactate dehydrogenase while digitonin treatment releases about 25% less. Sonication, being 
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the more disruptive method, released twice the citrate synthase activity compared t
o 
freeze/thawing and ten times the amount released by digitonin treatment. Digitonin wa
s 
therefore chosen as a method that preferentially releases cytoplasmic components from
 
trypsinized fibroblast cultures. Digitonin treatment also appeared to be more reproducibl
e 
than sonication in releasing CBS activity from trypsinized fibroblast cultures in previou
s 
studies in our laboratory (L. Human, personal communication). 
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Cystathionine f]-synthase assay 
Cystathionine j3-synthase irreversibly condenses homocysteine and serine to produce 
cystathionine. The assay for enzyme activity is based on the conversion of L-[1
4C-3J-serine to 
14C-cystathionine by lysates of fibroblast cultures. Reaction products are separated by 
chromatographic methods and the amount of radioactive cystathionine formed determined as 
a measure of the enzyme activity. One unit of enzyme activity is defined as the amount of 
enzyme that catalyses the formation of 1 nanomole of cystathionine per hour. Results are 
expressed as units of activity per milligram of protein measured in the lysate. The initial 
conditions for the assay were modified from Fowler et al (1978). Reaction mixtures contained 
1 SmM L-homocysteine (freshly prepared), SmM L-serine, L-[1
4C-3]-serine to a specific activity 
of -6300dpm/nmol, 1 mM pyridoxal-5-phosphate and 1 OOmM Tris, pH 8.6 in a final volume of 
50µ1 and were incubated at 37°C for 4h. Assay blanks, in which the cell lysates were 
replaced with sterile distilled water, were included in the initial experiments, and showed no 
activity. 
Separation of reaction products by amino acid analyser and TLC 
The assay was standardised in our laboratory using a Beckman System 6300 amino acid 
analyser coupled to a Gilson FC-203 fraction collector to separate the reaction mixture and to 
collect the cystathionine containing fractions. The appropriate fractions were counted in a 
liquid scintillation counter to measure enzyme activity. This process is time consuming and 
very labour intensive. Separation of the reaction mixture using thin layer chromatography 
was compared to the amino acid analyser method. 
Paper chromatography with isopropanol/formic acid/water (80/6/20) as mobile phase has 
been widely used to separate the reaction mixture of the CBS assay (Fowler et al, 1978). 
TLC using a cellulose stationary phase and a development time of -24 hours in the same 
mobile phase was found to be successful in separating the components of the reaction 
mixture. Reaction products were identified on the basis of their relative mobilities compared 
to that of known standards visualised with ninhydrin. Radiolabelled cystathionine was 
quantified on a Packard flat bed counter. The specific activity of the radiolabelled serine was 
determined by applying an aliquot of the reaction mixture to each developed TLC before 
counting. Nine specimens were divided in half and analysed by both methods, the results of 
which are given in table 2. The measured values were on average 10% less when TLC 
separated the reaction mixtures were compared to the amino acid analyser separated the 
reaction mixtures. As shown in Figure 3, values measured by both methods correlated well 
(r2=0.373). This is in spite of the fact that a narrow range of activities was present in these 
sets of data, amplifying the negative effect that the inherent variation in the measurements 
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has on the correlation between the two sets of data. TLC was therefore chosen as a 
convenient method of resolving the reaction mixtures. 
Specimen A B C D E F G H I 
AAA 21.8 22.0 21.8 22.3 18.7 22.5 24.2 23.1 24.1 
TLC 19.2 20.0 19.2 19.2 20.8 20.2 20.9 19.9 19.6 
Table 2. CBS activity (U/mg) measured in identical reaction mixtures separated either on an amino acid 
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Figure 3. Scatter plot showing CBS 
activity (U/mg) measured on specimens 
separated by TLC versus the identical 
specimens separated by amino acid 
analyzer. 
Variability of the CBS activity measured in Jysates of cultured cells 
Preliminary studies in our laboratory (L. Human, personal communication) have indicated that 
cystathionine ~-synthase activity measured in lysates of cultured fibroblasts and lymphoblasts 
is highly variable from one occasion to the next. In order to quantify this variation a control 
fibroblast culture (F958) at the third passage was seeded into three tissue culture flasks and 
maintained in the same culture medium. The cultured cells were assayed weekly in triplicate 
for a period of five weeks. Cells were fed with tissue culture medium two days prior to each 
assay. Substrate solutions were prepared independently for every assay. 
The result of this five-week experiment is shown in Figure 4. The enzyme activity, normalised 
for protein content, showed a fourfold increase between the fourth and seventh passages 
from 5.5 ± 1.29U/mg to 22.3 ± 1.62U/mg as illustrated in Figure 4a. Notably, the enzyme 
activity released from each of the three separate cultures changed in tandem. The variation 
between the replicates of each flask (average 8.0%) was less than the variation between the 
three identical flasks (average 14.6%). The protein concentration in each lysate is shown in 
Figure 4b and the absolute enzyme activity, not corrected for protein content in Figure 4c. 
The amount of protein released from each culture remained relatively constant over the 
course of the five-week period, while the absolute activity of each replicate shows the same 
variation as the normalised enzyme activity. Additionally, higher protein concentrations could 
not be correlated with lower or higher normalised enzyme activities. These observations 
suggest that the large between-experiment variation is likely due to differences in the enzyme 
activity produced by the cells rather than changes in the total protein in each lysate. 
Various factors that may contribute to the variation in enzyme activity were investigated, 
including the effect of changing substrate solutions from one assay to the next. A single 
lysate of a control fibroblast line (F97 4) was assayed five times with different substrate 
solutions of the same composition. Separately made up reagents were L-serine, L-
homocysteine, pyridoxal-5-phosphate and the Tris reaction buffer. L-[1
4C-3)-serine could not 
be varied as it was obtained from a commercial source. The enzyme activity measured for 
the five different sets of substrate solutions was 15.9 ± 2.03 (12.7%) U/mg. This variation 
was very similar to the variation seen within the triplicates of one flask (average 8.0%) as well 
as between different flasks (average 14.6%) in the previous experiment. Slight variations in 
substrate and co-factor concentrations were therefore excluded as the main source of the 
large changes in enzyme activity seen over the five-week period in the previous experiment. 
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Variable release of either total protein or CBS activity from fibroblast cultures by digitonin was 
investigated as a possible factor contributing to the observed variation. A cell pellet of a 
trypsinized control fibroblast line (F992) was divided into four equal parts, and each part was 
treated with a separately prepared digitonin solution. Enzyme activity was assayed for each 
lysate at 25mM serine, 20mM homocysteine and 1mM PLP. 
14C-serine was added to a 
specific activity of -630dpm/nmol. The amount of enzyme activity that was not released from 
the cells but remained associated with the cell debris was estimated by washing the cell pellet 
with 50µ1 PBS and assayed for CBS activity under exactly the same conditions. CBS activity, 
protein concentration and the percentage of the absolute enzyme activity not released from 
the cells are given in table 3. 
CBS activity (U/mg) [Protein] (mg/ml) % activity remaining 
35.1 1.93 11.3 
36.5 2.00 10.5 
37.2 1.83 9.1 
41.8 1.78 10.1 
Table 3. CBS activity (U/mg), protein concentration (mg/ml) and percentage of absolute activity 
remaining in the cell pellet after lysis of four identical cell pellets treated with four individual digitonin 
solutions. 
The average CBS activity for the four flasks was 37.7 ± 2.9 (7.7%) U/mg. The variation in the 
activity released with each of the digitonin solutions was similar to the observed within 
replicate variation. The total protein released from the cells by each digitonin treatment 
similarly showed little variation with an average of 1.89 ± 0.1 O (5.2%) mg/ml being released. 
Additionally, an almost constant fraction of the total enzyme activity remained associated with 
the cell debris after each digitonin treatment. Taken together, this data indicates that lysis of 
the fibroblast cells with digitonin released a reproducible amount of the total protein as well as 
enzyme activity and did not contribute greatly towards the observed variation. 
After trypsinization cells were resuspended in complete medium to inhibit trypsin activity and 
washed twice with ice cold PBS. Any foetal calf serum protein remaining after washing would 
affect the calculated enzyme activity. A control fibroblast line (F992) was trypsinized in the 
usual manner divided into six equal parts. Pairs of the suspensions were either directly lysed 
with digitonin, or washed either once or twice with ice cold PBS and subsequently lysed with 
digitonin. Enzyme activity was assayed as using -263dpm/nmol 
14C-serine under conditions 
of maximal activity described in the kinetics section. The enzyme activity obtained for each 
duplicate treatment is given in table 4. 
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Number of washes none one 
two 
Replicate A 153.2 144.0 
146.2 
Replicate B 144.9 149.7 
157.7 
Table 4. The effect of washing cell pellets with PBS on CBS activity (U/mg). Pairs of the sus
pensions 
were either directly lysed with digitonin, or washed either once or twice with ice cold
 PBS and 
subsequently lysed with digitonin. Lysates were subsequently assayed for CBS activity as d
escribed in 
the text. 
The calculated enzyme activity remained constant, irrespective of the number of washes the 
cell pellet was subjected to before lysis. A gradual almost linear reduction was observed in 
the amount of protein measured in the lysates. In view of the constant enzyme activity, this is 
most likely due to loss of intact cells in each wash step. 
CBS activity measured in the lysates of fibroblast cultures is normalised to the protein content 
of each lysate. Variability in the protein assay will directly influence the calculated enzyme 
activity. The reproducibility of the Biorad protein assay was investigated by assaying five 
replicates of a lysate of a control fibroblast line on three consecutive days. The standard 
deviation between experiments was 5.0% of the mean and 2.5% of the mean within each 
experiment. The variation in protein measurement was too little to affect the calculated 
enzyme activity drastically. The presence of digitonin did not interfere with the Biorad assay. 
The reproducibility of the enzyme assay itself was investigated by freezing aliquots of a cell 
pellet as well as aliquots of a lysate obtained from the same cell pellet at -70°C and assaying 
CBS activity every fNe days. The identical cultured cells were also trypsinized, reseeded and 
assayed on each occasion. The enzyme activity obtained from the lysates of the growing 
cultures and the frozen cell pellets as well as the frozen lysates is illustrated in Figure 5. CBS 
activity measured in lysates of the frozen cell pellets and the frozen lysates showed little 
change when assayed repeatedly over a period of two weeks, indicating that the enzyme 
assay itself is reproducible. There was no loss of activity after two weeks at -70°C. The 
enzyme activity measured in lysates of the identical cell culture grown in parallel with the 
assays varied markedly. This suggests that factors during the culture of the fibroblast cells 
most likely have the greatest contribution to the large variation when measuring the enzyme 
activity released from cultured fibroblasts at different times. The activity released from the 
frozen cell pellets was also constantly about 10% higher than that of the frozen lysates, 
suggesting that the freezing and thawing of the cell pellets had released additional enzyme 
activity. 
In an attempt to determine the influence that cell density may have on the measured enzyme 
activity, equal amounts of a control fibroblast line (F992) was seeded into eight tissue culture 
flasks. A pair of flasks was subsequently assayed for CBS activity every week for four weeks. 
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Tissue culture conditions were kept constant by feeding cells twice a week with one change of 
medium occurring two days before each assay. The first pair of flasks that were assayed had 
already reached confluence by the time of the assay. Enzyme activity measured on lysates of 
the duplicate flasks over the four-week period is shown in Figure 6. Very little change in 
enzyme activity could be detected during the entire experiment, suggesting that the 
fluctuations in activity might be associated with the state of the cultures prior to reaching 
confluence. Once the cultures have attained confluence the enzyme activity seems to remain 
stable. 
120 • I Figure 6. CBS activity measured over a i 
I i period of four weeks in identical cultures that 100 -i 
were started at the same time and fed twice a 
• week. The cultures had reached confluence CJ 80 _j • • E -- • • when the experiment was started and were ::J • 
~ • 
s 60 allowed to grow more conflu
ent with time. A 
·u pair of flasks was sacrificed and assayed on ro 




2 3 4 
week number 
42 
Table 5 gives a summary of the factors investigated and the variation measured in each 
experiment. Variation is expressed as the standard deviation of the replicate measurements 
as a percentage of the mean of the measurements. 
Source of variation Variation 
Replicates of the same lysate 8.0% 
Replicates of different flasks of identical cultures 14.6% 
Between identical cultures on different occasions A 49.7% 
Between substrate solutions 12.7% 
Between lysis solutions 7.7% 
Between wash procedures 1.7% 
Between protein determinations 5.0% 
Between identical lysates on different occasions 11.3% 
Between identical pellets lysed on different occasions 9.3% 
Between identical cultures on different occasions B 52.1% 
Between identical, highly confluent cultures on different occasions 16.2% 
Table 5 Summary of the factors influencing measured CBS activity and the variation measured in each 
experiment. Variation is expressed as the standard deviation of the replicate measurements as a 










Kinetic properties of CBS in lysates of cultured fibroblasts 
The kinetic properties of CBS in lysates of cultured fibroblasts were investigated in an attempt 
to define the conditions under which maximal enzyme activity could be achieved. Titrations 
were performed for serine, homocysteine and pyridoxal-5-phosphate. Lysates of a control 
cell line (F992) were used as a source of CBS activity for the assays. 
The serine titration was performed at 20mM homocysteine and 1 mM PLP. The serine 
concentration was varied between 2.5 and 15mM. The results represent the mean of 
duplicate measurements. Figure 7 shows CBS activity plotted as a function of serine 
concentration. A Michaelis-Menten curve was fitted to the data (Figure 7a) using non-linear 
regression. A Lineweaver-Burk plot was drawn from the reciprocal of the reaction rate and 
substrate concentration (Figure 7b). The apparent Km of the enzyme for serine was 10.2mM 
determined with the Michaelis-Menten fit and 7 .2mM using the reciprocal plot. These values 
correspond well with the previously published 4mM obtained for cystathionine beta-synthase 
purified from human liver (Kraus, 1987). The maximal enzyme activity CvmaJ was estimated 
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Figure 7a. CBS activity as a function of serine 
concentration. Assays were performed in 
duplicate and the fitted curve is described by the 
Michaelis-Menten equation. 
Figure 7b. Lineweaver-Burk plot showing the 
inverse of the reaction rate plotted as a function 
of the inverse of the substrate concentration. 
Each point is the average of duplicate 
measurements. 
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The homocysteine titration was performed using 1 SmM serine, -21 OOdpm/nmol 
14C-serine 
and 1 mM PLP. Homocysteine was varied between O and 60mM. Each point represents the 
mean of triplicate measurements and the experiment was performed twice to verify the 
results. CBS activity is plotted as a function of homocysteine concentration in Figure 8. 
Maximal CBS activity was observed at 20mM homocysteine. The curve is fitted to the data 
according to an equation describing substrate inhibition: v=Vmax·S/(Km+S+S'/Ki), where v is 
the reaction rate, Vmax the maximal velocity, Km the apparent Michaelis constant, Ki the 
inhibition constant and S the substrate concentration. The apparent Km obtained for the fitted 
data was 8.4mM, Vmax 84U/mg and K1 39.0mM. The apparent Km agreed with the measured 
value of 25mM reported by Kraus for CBS purified from human liver (1987). Product inhibition 
was excluded by performing the assay at 1 OmM homocysteine and cystathionine between 0 
and SmM. No inhibition of CBS activity was noted as a function of cystathionine 
concentration. Additionally, only about 1 % of the radiolabelled serine is converted to 
cystathionine in the 4 hour period of the assay, making it unlikely that product could 
accumulate to levels sufficient to inhibit enzyme activity. Fleisher et al (1973) illustrated 
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Figure 8. CBS activity as a function of 
homocysteine concentration in a lysate of 
control fibroblast line F992. Each point 
represents the mean of 3 measurements with 
the error bars showing the standard deviation 
from the mean. The fitted curve was drawn 
from an equation describing substrate 
inhibition. 
The pyridoxal 5-phosphate titration was performed at 20mM homocysteine, SmM serine with 
the 14C-labelled serine at a specific activity of -6300dpm/nmol. Pyridoxal 5-phosphate is a 
tightly bound co-factor and the presence of 0.02mM pyridoxal in the tissue culture medium 
could allow the enzyme to be saturated with its co-factor. No change in enzyme activity was 
apparent when the PLP concentration was increased from 0.25 to 2.00mM. This finding 
disagrees with a previous report (Fleisher et al, 1973) in which a threefold increase in enzyme 
activity was measured upon the addition of 1.25mM PLP. 
The conditions of maximal activity were defined as 40mM serine, 2mM pyridoxal-5-
phosphate, 1 OOmM Tris, pH 8.6. Further activation of CBS activity was achieved by the 
addition of SmM propargylglycine and 1 mM S-adenosylmethionine. Propargylglycine is an 
inhibitor of y-cystathionase, which cleaves cystathionine to cx.-ketobutyrate and cysteine. 
Although very little cysteine was detected during previous assays, propargylglycine was 
added as a cautionary measure. S-adenosylmethionine is an allosteric activator of CBS and 
enzyme activity shows a threefold increase in response to an increase in SAM concentration 
from Oto 1 OOµM (Kluijtmans et al, 1996). 
-1-6 
CBS activity in PVD patients 
The standardised enzyme assay was subsequently used to investigate a group of 
hyperhomocysteinaemic patients suffering from peripheral vascular disease. The group 
consisted of non-diabetic, non-smokers to whom no known clinical reason for their condition 
could be ascribed. CBS activity was assayed in lysates of fibroblast cell lines obtained from 
the PVD group as well as a group of age and sex matched controls (mainly parents of 
patients who tested negative for suspected mitochondrial disorders). Three known 
homozygotes for CBS deficiency and three obligate heterozygotes were included in the 
experiment. The assays were all performed with lysates prepared on the same day and 
processed in a random order. All cultures had been in a highly confluent state for at least a 
week before the assay was performed. 
Assays were performed under the conditions established to produce maximal activity as well 
as under conditions of sub-maximal activity, with substrate concentrations close to their 
measured Km's to determine which would best discriminate between the control and 
heterozygote groups. Assaying under conditions with substrate concentrations at or below 
Km, should reveal any mutations affecting the affinity of the enzyme for its substrate. The 
sub-maximal conditions where 1 OmM homocysteine and 5mM serine. The values obtained 
for groups were compared using a two-tailed Students t-test. 
Figure 9 (top) shows the enzyme activity obtained under conditions of maximal activity for the 
control and PVD patient groups as well as the homozygotes and obligate heterozygotes for 
CBS deficiency. The average enzyme activity for the control group was 46.6 ± 17.0 U/mg and 
the 95% confidence interval between 12.6 and 80.6 U/mg under conditions of maximal 
activity. The enzyme activity measured in the heterozygote group was 32.6 ± 15.3 U/mg, 
which was not significantly different from the control group. Surprisingly, the one 
homozygous cell line that was assayed under conditions of maximal activity showed activity at 
14.2 U/mg, which can most likely be ascribed to stimulation of residual enzyme activity by 
pyridoxal 5-phosphate and S-adenosyl methionine. 
In the PVD group, the enzyme activity ranged between 13.5 and 64.0 U/mg. The average 
enzyme activity was 36.6 ± 16.2U/mg, which does not differ significantly from the activity in 
the control group. None of the cell lines from the PVD group showed enzyme activity outside 
of the 95% confidence interval of the control group. The only cell line that showed CBS 
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Figure 9. CBS activity measured in the PVD group, an age and sex matched control group, three 
known homozygotes and three obligate heterozygotes for CBS deficiency. The activity of each cell 
line in the PVD group (972 to 1000) is also shown individually. The assay under conditions of 
maximal activity is shown in the top figure, under conditions of sub-maximal activity in the middle 
figure, and on a second occasion under conditions of sub-maximal activity in the bottom figure. 
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Figure 9 (middle) shows the enzyme activity obtained on the identical lysates using conditions 
of sub-maximal activity. The enzyme activity measured under conditions of sub-maximal 
activity appeared to better discriminate between the control and heterozygote groups 
compared to the conditions of maximal activity. The enzyme activity measured in the control 
group under conditions of sub-maximal activity was 7 .1 ± 2.5 U/mg and the 95% confidence 
interval between 2.1 and 12.1 U/mg which corresponds with previously published data using 
similar assay conditions (Fowler, 1978 and Kluijtmans, 1996). 
The enzyme activity measured in the group of obligate heterozygotes was 3.5 ± 0.7 U/mg, 
which is significantly different from the activity measured in the control group (P<0.01). There 
is however some over1ap between the two groups as has been reported by McGill et al 
(1990). The enzyme activity measured in the patients homozygous for CBS deficiency 
showed reduced activity at 1.8, 2.0 and 0.2 U/mg respectively. The enzyme activity in the 
PVD group ranged between 2.1 and 6.3, all of which are within the 95% confidence interval 
for the control group. The average enzyme activity of the PVD group was 4. 7 ± 1.4 U/mg, 
which is significantly different from that of the control group (P<0.05). Once again, as with the 
assay under conditions of maximal activity F1000 was the only cell line to show activity very 
close to the lower 951h percentile of the control range (2.1 U/mg). Patients 974, 979 and 980 
could not be assayed under these conditions, as insufficient material was isolated from their 
cultured cells. 
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The enzyme activity measured under conditions of sub-maximal activity corresponded well 
with the activity obtained under conditions of maximal activity, with a correlation coefficient of 
0.76 between the two sets of data. The scatter plot of enzyme activity under conditions of 
maximal activity versus enzyme activity under conditions of sub-maximal activity is illustrated 
in Figure 10. 
On average the enzyme activity was about 6 times higher using the conditions of maximal 
enzyme activity. This increase in activity is most likely due to an estimated threefold increase 
in enzyme activity when adding S-adenosylmethionine to 1 mM, as reported by Kluijtmans 
et al (1996), as well as an estimated 2.5 fold increase in activity when increasing serine from 
5 to 40mM, using in the values obtained from the serine titration. The addition of 2mM 
pyridoxal 5-phosphate and the increase in homocysteine from 10 to 20mM may also make 
slight contributions to the increase in activity. 
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Figure 11. Correlation between CBS activity 
measured in lysates of fibroblast cultures of 
the control and PVD groups under conditions 
of sub-maximal activity in the first (y-axis) and 
second (x-axis) experiment 
The whole experiment was repeated under conditions of sub-maximal activity to investigate 
the reproducibility of the assay, the result of which can be seen in Figure 9 (bottom). Cell 
cultures were seeded again after the first experiment and allowed to grow for two weeks to 
ensure that all cultures had reached confluence. Cultures were fed twice a week and two 
days before the assay. The control group displayed an average enzyme activity of 4.3 ± 2.1 
U/mg. These values were as a group significantly lower than the values obtained for the 
control group in the previous experiment (P<0.01). Both the homozygote and heterozygote 
groups also showed lower activity than in the previous experiment. The heterozygote group 
displayed an average enzyme activity of 0.9 ± 0.8 U/mg, while all the homozygotes showed 
activity below 1 U/mg. The activity measured in the PVD group ranged between 2.0 and 10.4 
50 
U/mg with an average of 4.3 ± 2.4 U/mg. The enzyme activity measured in the PVD group 
was not significantly different from that of the control group (P>0.9), which is contradictory to 
the first experiment. The average enzyme activity measured for the PVD group was also not 
significantly different from that of the first experiment. The correlation between the values 
obtained for the two experiments was low (correlation coefficient <0.5) and the scatter plot is 
shown in Figure 11. 
The above mentioned data illustrates that regardless of the precautions taken the individual 
measurements still show great variability. The only constant effect was the average 
differences between the control, heterozygous and homozygous patient groups. Thus, the 
only way to currently identify a patient as a likely candidate for heterozygosity for CBS 
deficiency is to show that the enzyme activity released from cultured fibroblasts is 
reproducibly low when compared to a panel of control cell lines on a number of occasions. 
The only patient in the PVD group that met these criteria was patient 1000. The enzyme 
activity released from this cell line was low compared to the control range in two experiments 
(2.2 and 2.0 U/mg), under conditions of maximal activity in the same experiment (13.5 U/mg). 
The enzyme activity was found to be low in another experiment using conditions of maximal 
activity (10.4 U/mg). Patient 960, suffering from homocystinuria, consistently showed virtually 
no detectable CBS activity. The patient's mother (960) showed CBS activity in the 
heterozygote range (5.1 and 2. 7 U/mg) that was lower than a control cell line (959) assayed in 
parallel (14.8 and 14.2 U/mg). The values obtained for the mother was however in the range 
that overlaps with the established normal range and viewed in isolation they would not have 
suggested heterozygosity for CBS deficiency. 
The association of CBS activity in lysates of fibroblast cultures with fasting and post 
methionine load plasma homocysteine levels was also investigated. The correlation between 
plasma homocysteine and CBS activity is graphically illustrated in Figure 12 as scatter plots 
of fasting plasma homocysteine, post methionine load plasma homocysteine and change in 
plasma homocysteine versus CBS activity measured in the two above-mentioned 
experiments under both conditions of maximal and sub-maximal activity. 
In the first experiment, both using conditions of maximal and sub-maximal activity there is a 
slight negative correlation between both the fasting and post methionine load plasma 
homocysteine levels measured in the patients and the CBS activity measured in lysates of the 
cultured fibroblasts. This finding could not, however, be reproduced in the repeat experiment 
as no clear correlation could be observed between any of the homocysteine measurements in 
plasma and CBS activity. There was also no clear correlation · between the change in 
homocysteine level between the fasting and post methionine load state and enzyme activity in 
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Figure 12. Correlation between fasting plasma homocysteine (top row), post methionine load plasma 
homocysteine (middle row) and change in plasma homocysteine (bottom row) AND CBS activity measured under 
conditions of maximal activity (first column) and conditions of sub-maximal activity (middle column) in the first 
experiment and second experiment (last column). 
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Molecular Results 
The aim of the molecular techniques applied during this study was to identify the exact 
genetic mutations in the CBS gene leading to the production of dysfunctional enzyme and 
decreased activity. Patient 1000 as well as patient 960 and her mother, 961 were 
investigated. 
mRNA was extracted from cultured lymphoblasts and fibroblasts using the acid guanidinium 
thiocyanate-phenol-chloroform method of Chomczynski and Sacchi (1987). Diethyl 
pyrocarbonate treated water and RNase free pipette tips were used in these procedures to 
prevent the degradation of the isolated message by contaminating RNases. The quality of 
the preparations was assessed by measuring the ratio of the absorbance at 260nm to 280nm. 
The A20012ao ratio in all preparations exceeded 1 . 7. cDNA was reverse transcribed from the 
isolated mRNA using an oligo dT primer and AMV reverse transcriptase. 
cDNA was amplified with the polymerase chain reaction (PCR) using Thermus aquaticus DNA 
polymerase (Taq). PCR products were size separated by agarose gel electrophoresis and 
visualized by ethidium bromide staining and UV detection. All PCR's were optimized by 
initially performing the reactions at 2mM MgCl2 and at an annealing temperature 2°c below 
the theoretical melting temperature of the primer with the lowest melting point. If no product 
was observed, the annealing temperature was dropped by another two degrees in a stepwise 
fashion until a reasonable amount of product was formed. If many non-specific products were 
observed the annealing temperature was similar1y raised in 2°c steps until a balance was 
achieved between yield and specific product. Once the optimum temperature had been 
established a MgCl2 titration was performed between 1 and 4mM MgCl2 in increments of 
O.SmM. Again, the MgCl2 concentration yielding the most product and highest specificity was 
subsequently used. An extension time in excess of 1 minute per thousand base pairs 
amplified was generally used. 
For the purpose of direct sequencing the CBS cDNA was amplified in two over1apping 
sections of about 1000bp each. A semi-nested approach using three primers in two rounds of 
amplification was followed in both cases. The 5' section was amplified using the primers CBS 
f-107 and CBS r1393 for 40 cycles in the initial round of amplification. The PCR products 
from the initial amplification were subjected to a second round of amplification using primers 
CBS f-57 and CBS r1393 for 30 cycles. The temperature profile comprised denaturing at 
94°C for 45s, annealing at S0°C for 45s and extension at 72°C. Extension time was 
increased in a stepwise manner and was 120s during the first thirteen cycles, 150s during the 
middle thirteen cycles and 180s during the last thirteen cycles in the first round of 
amplification. During the second round of amplification the extension time was increased in a 
similar fashion every ten cycles. The 3' section of the CBS cDNA was amplified in a similar 
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fashion using the primers CBS f1106, r1955 and r1928 and an annealing temperature of 
54°C. In both cases the optimal MgCl2 concentration was established to be 2mM. 
PCR products were subsequently purified by resolving the products on an agarose gel, 
physically cutting out the desired band and extracting the DNA from the gel slice using a 
Qiaex II gel extraction kit from Qiagen. Cleaned PCR products were subsequently directly 
sequenced at the Core Facility at UCT using internal primers and dye labeled dideoxy 
terminators. A Thermosequenase cycle sequencing kit (Amersham Life Science) was used 
with an ABI 373 DNA sequencer (Perkin Elmer). Direct sequencing of PCR products, 
however, proved to be an inappropriate method for searching for different mutations on two 
alleles over 2000 base pairs. Heterozygous mutations show up as two peaks or bands, one 
for the normal base and one for the altered base. Due to background signals quite a number 
of bases show two signals, which makes it virtually impossible to identify the true mutations. 
Cloning of PCR products was utilized as a solution to this problem. Each clone represents 
only one allele and any changes show up distinctly upon sequencing. A 1985bp PCR was set 
up spanning the entire coding region of the CBS cDNA using a nested approach. The 
primers CBS f-107 and CBS r1955 were used for 40 cycles in the initial round of amplification. 
The PCR products from the initial amplification were subsequently further amplified using 
CBS f-57 and CBS r1928 for 30 cycles. The temperature profile comprised denaturing at 
94°C for 45s, annealing at 54°C for 45s and extension at 72°C. Extension time was 
increased in a stepwise manner and was 120s during the first thirteen cycles, 180s during the 
middle thirteen cycles and 240s during the last thirteen cycles in the first round of 
amplification. During the second round of amplification the extension time was increased in a 
similar fashion every ten cycles. Figure 13 shows the MgCl2 titration for the above mentioned 
PCR. The optimal MgCl2 concentration for this PCR is 1.5mM, yielding the greatest amount 
of product and only one specific band with an apparent size of -2000bp. The products of the 
first and second rounds were loaded successively. No product is visible after the first round 
of amplification illustrating the need for two rounds of PCR to amplify the low copy number 
CBS mRNA. 
Cleaned PCR products were ligated into the plasmid vector pGEM-T, which contains an 
Ampicillin resistance gene and the /acZ gene in the multiple cloning site allowing for 
blue/white selection of insert-containing vector. pGEM-T also carries single 5' thymidine 
overhangs, which are complementary to single 3' adenosine overhangs in the PCR products 
created by Taq polymerase's terminal transferase activity. This feature facilitates the direct 
cloning of PCR products into pGEM-T. PCR product was added in a molar ratio of 5:2 to the 
plasmid as recommended, and the manufacturer's protocol followed exactly. 
54 






Figure 13. MgC'2 titration of a 1985bp PCR 
amplifying the entire coding region of the 
CBS cDNA. The MgC'2 concentration of 
each reaction is given below each lane in 
mM. The initial and nested amplifications for 
each reaction were loaded in successive 
lanes. The lane marked A represents A-DNA 
digested with Hindlll 
Competent XL 1 Blue E.coli cells were produced by RbCl2 treatment and transformed with the 
ligated vector using a 30 second heat shock at 37°C. Transformed bacterial cultures were 
plated onto LB agar plates containing Ampicillin and coated with Xgal and IPTG and grown 
overnight at 37°C. White colonies, carrying insert-containing vector, as well as a few of blue 
colonies were streaked onto fresh Ampicillin-containing LB agar plates and grown overnight at 
37°C. The transformatioi:a efficiency was calculated by transforming the competent cells with 
1 ng of pUC18 plasmid, which is of similar size as pGEM-T. The transformation efficiency was 
reproducibly found to be 107 colony-forming units per microgram of DNA. 
Single colonies were grown overnight at 37°C in LB broth containing Ampicillin. Plasmid DNA 
was prepared using the alkaline lysis miniprep method of Birnboin and Doly (1979) or a 
commercial Wizard Plus SV miniprep kit (Promega). Bacterial cells were sedimented by 
centrifugation, resuspended in buffer, lysed and proteins and nucleic acids denatured by 
adding SOS and NaOH. Potassium acetate was added to neutralize the mixture causing 
plasmid DNA to re-anneal rapidly and SOS, bacterial proteins and chromosomal DNA to 
precipitate. Precipitated material was subsequently removed by centrifugation. Hereafter 
different means of purifying the plasmid DNA were employed by the two methods. A spin 
column, containing a porous silica gel matrix to bind DNA at acidic pH and filter any 
precipitated contaminants was used in the commercial kit. After two washes, DNA was eluted 
at neutral pH with sterile distilleq water. The method of Bimboin and Doly used 
phenol/chloroform/isoamyl alcohol and chloroform extractions to remove contaminants, where 
after DNA was washed by precipitating with ethanol. Precipitation of the -plasmid DNA with 
polyethylene glycol at a high salt concentration was added as a further purification step. PEG 
was dissolved and plasmid DNA precipitated in 70% ethanol and DNA dissolved in sterile 
distilled water after drying. 
Plasmids were purified from white colonies, which should contain insert-containing vector as 
well as blue colonies, which contain self-ligated vector. The plasmids isolated from the blue 
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colonies are used as a size marker, to show that recombinant plasmid vectors of higher 
molecular weight had indeed been isolated from the white colonies. Figure 14 shows the 
purified plasmids resolved on a 1 % agarose gel visualized with ethidium bromide. The first 
lane contains a DNA size marker and the last, plasmid isolated from a blue colony, which 
contains no insert. As is clear from the sizes of the bands in lanes A to D, most plasmids 
isolated from white colonies are of higher molecular weight and therefore contain an insert. 
Some of the white colonies however, yielded plasmids of the same apparent size as the self-
ligated vector (lane E) and contained no insert. The higher molecular weight plasmids all 
appear to be of the same size, and should therefore all contain either one of the alleles as an 
insert. 





Figure 14. Plasmid minipreps separated on a 1% 
agarose gel and visualized with ethidium bromide. 
The right hand lane represents a linear siz,e 
marker (A DNA digested with Oral). The lanes A 
to E represent plasmids purified from white 
colonies. The l~ft hand lane (blue) represents 
plasmid purified from a blue colony, which 
contains no insert. The numbers on the right give 
1057 the sizes of the standards in base pairs. 
Manual sequencing was employed to confirm the identity as well as the orientation of the 
insert. A Sequenase DNA sequencing kit (Amersham Life Science), which is based on the 
Sanger dideoxy nucleotide sequencing method was used with a commercially obtained M13 -
40 forward sequencing primer. [a-35S]-dA TP was used as a label to visualize the reaction 
products using autoradiography. Plasmid DNA was denatured under basic conditions with 
NaOH and single stranded molecules selec;:tively renatured upon neutralization with ice cold 
sodium acetate. DNA was sedimented with 100% ethanol, washed with 70% ethanol and 
dissolved in sterile distilled water. The primer was annealed at 37°C for 30 minutes and 
extension allowed to occur for 3 minutes at ambient temperature. Extension was ter'minated 
by adding the respective dideoxy nucleotides. The reaction products were separated on a 6% 
polyacrylamide gel and exposed to autoradiography film for 72h. Figure 15 shows an 
example of a portion of a typical sequencing autoradiograph. Both the upstream plasmid 
sequence as well as the sequence of the insert, starting at the primer can be read using the 
M13 -40 forward sequencing primer. 
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Figure 15. Autoradiograph of a sequencing reaction resolved using 
polyacrylamide gel electrophoresis. This autoradiograph shows the sequence 
of a clone of the CBS cDNA obtained from patient 960. The clone was 
sequenced with the M13 -40 forward sequencing primer that appears 
upstream from the multiple cloning site. The upstream plasmid sequence is 
annotated in bold lettering while the insert sequence starting at the beginning 
of the primer CBS f-56 annotated in normal lettering. The red T represents an 
A to T change that is likely due to Taq polymerase error as it was not found in 
any of the other sequenced clones. 
Plasmids containing the correct insert were sequenced on an automated sequencer to obtain 
longer sequences. This was performed at the Department of Biochemistry anct Microbiology 
at UCT on a ALFexpress DNA automated sequencer, using a ThermoSequenase fluorescent 
labeled primer cycle sequencing kit. The M13 -40 forward and reverse sequencing primer 
labeled with a fluorescent dye was used in the reactions. Sequencing of the vector constructs 
with the M13 sequencing primers covered 750bp in the forward and 750bp in the reverse 
direction, leaving the middle - 500bp unsequenced. The middle section of the CBS cDNA 
was sequenced at the Core Facility at UCT using the internal primers CBS f560, f769 and 
f1106. 
Patient 960 was identified as a compound heterozygote, carrying a different mutation on each 
allele. The first mutation was confirmed as a duplication of the 7 bases between position 
I 
1553 and 1559. The 7 base pair insert leads to a frameshift and premature termination of the 
protein, affecting the last 32 amino acids of the 551 amino acid CBS monomer. The 
sequencing profile for the mutant allele as well as the normal sequence is illustrated in Figure 
16. Figure 17 shows the translated sequence for the last 41 amino acids for the normal CBS 
sequence compared to the mutant sequence. This mutation was found to novel and 
deposited at the CBS Database (http://www.uchsc.edu/sm/cbs/cbsdata/cbsmain.htm). The 
second mutation was confirmed in three clones as well as the patient's cDNA as the common 
G919A transition leading to a glycine to serine substitution at amino acid 307. The 
sequencing profiles of both the patient cDNA as well as a normal control are shown in Figure 
18. These were sequenced with an internal primer, CBS f769. This mutation creates an A/ul 
site and was confirmed in other clones and in the patient cDNA by restriction digest of a 
443bp PCR product of primers CBS f769 and r1212. The normal PCR product is digested 
into four fragments of 31 , 75, 124 and 213bp, while the 213bp fragment is digested to a 44 
and 169bp fragment in the PCR product of the mutant allele. The restriction digest of the 
PCR products is illustrated in Figure 19. Both the normal and mutant sequence at position 
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919 are present in the patient, whose restriction digest products shows both the 169 and 
213bp bands, while only the normal sequence is present in the mother, who's 213bp PCR 
fragment remains undigested. 
Cloned CBS cDNA from patient 1000 was sequenced to determine the mutation/s leading to 
decreased enzyme activity and mild hyperhomocysteinaemia in the patient. An A to G 
transition was identified at nucleotide 695 in two clones out of seven sequenced clones. No 
other mutations were consistently found in any of the remaining clones. This mutation leads 
to the substitution of a histidine for an arginine at amino acid 232 (H232R). The sequencing 
profiles for the normal and mutant alleles are shown in Figure 20. 
A C TT CCC GG T G C T G T GG T C T G T GG T A C TGG A T C T G C T C 
I ' ' ' " ' I ' 
A C T T C C C GG T G C T G TGGT A C TGG AT C T G C TC G T GCACCACC 
Figure 16. Sequence profile 
of the complementary strand 
of a mutant allele of patient 
960 showing the 7bp 
duplication (top) and the 




V V H E Q I Q Y H S T G K S S Q R Q M V 
GTGGTGCACGAGCAGATCCAGTACCACAGCACCGGGAAGTCCAGTCAGCGGCAGATGGTG 




V V H E Q I Q Y H R P Q H R E V Q S A A 
GTGGTGCACGAGCAGATCCAGTACCACAGACCACAGCACCGGGAAGTCCAGTCAGCGGCA 
D G V R G G H R H * 
GATGGTGTTCGGGGTGGTCACCGCCATTGACTTGCTGAACTTCGTGGCCGCCCAGGAGCG 
GGACCAGAAGTGA 
Figure 17. Translated sequence for the last 41 amino acids of the normal CBS sequence compared to 
the insert containing mutant CBS allele in patient 960. The normal sequence is shown on top while the 
mutant sequence is shown at the bottom. The duplicated bases are underlined and the amino acid 
changes in bold lettering. The stop codon for each reading frame is shown as a star. 
G G G A T c(!) G C T A C Figure 18. 
Sequencing profiles of both the 
patient's cDNA as well as a normal control. This 
sequence shows the G919A transition that leads 
to a glycine to serine substitution at amino acid 
307. The changed base is circled. 
GG G A T C GG C T A C 
960 961 F G 100bp 
AACCCCC T GGCT CQCT ACG A CC ACC 
AACCCCC T GGCTCACT ACG A CC ACC 
200 
Figure 19. A/ul digest of a 443bp PCR product 
from cDNA of patient 960, his mother (961 ), and 
two clones of the patients' cDNA (F and G) 
containing the G919A transition. The PCR 
product is digested to four fragments, 31 , 75, 124 
100 and 213bp in length in the normal sequence and 
the 213bp fragment is further digested to two 
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fragments, 44 and 169bp in length in the mutant. 
The mother shows no 169bp band while the 
patient shows both alleles (213 and 169bp). The 
right hand lane shows a 1 OObp ladder. 
Figure 20. Sequencing profile of cloned CBS 
cDNA of patient 1000. The top profile shows the 
sequence of the mutant allele, with the A to G 
transition at nucleotide 695 underlined. The 
bottom sequence shows the normal allele of the 
same patient. This transition leads to a histidine 
to an arginine substitution at amino acid 232 
(H232R). 
Dual metabolic labeling 
The metabolism of methionine in cultured fibroblasts was investigated using two radiolabeled 
isotopes of methionine. L-[35S]-methionine was used to follow methionine through the 
transsulfuration and remethylation pathways, while L-[methyl-
3HJ-methionine was used as a 
marker for methyl transfer reactions. Figure 21 shows the metabolism of methionine with the 
metabolites that the 35S and tritium labels can be incorporated into in yellow and blue 
respectively. The 35S radiolabel can be incorporated into protein directly as methionine or 
after being metabolized through the transsulfuration pathway, as cysteine. The tritium 
radiolabel, however is on the methyl group of methionine, and is transferred to a methylated 
acceptor, mainly nucleic acid and protein. Changes in the flux through the transsulfuration 
and remethylation pathways, such as caused by enzyme deficiencies, could therefore affect 
the ratio of tritium to 35S incorporated into acid precipitable material. Confluent fibroblast 
cultures were incubated in pre-warmed buffer or tissue culture media containing the isotopes. 
At various time intervals culture medium was removed, the cultures washed with saline and 
protein and DNA precipitated from the cultures with 5% trichloracetic acid. The precipitated 
material dissolved in 0.5M NaOH. The culture medium, as well as the acid soluble and acid 
precipitable fractions obtained from the cultures at each time point was counted in a 
scintillation counter. A O to 200keV window was used to detect tritium (which includes a 
defined contribution from 
35S) and a 400 to 600keV window was used to detect only 
35S. The 
amount of each isotope was calculated for the medium, the TCA soluble fraction containing all 
the small molecular components and the TCA precipitated macromolecules. 
The initial experiments focussed on the effects of different culture media on the uptake and 
incorporation of the labels into acid precipitable material. The first medium that was used was 
a balanced salt solution (Medium Z) containing 1g/L glucose as carbon source. A control cell 
line was followed over a period of 2 hours and the results of this experiment are shown in 
Figure 22. The rapid entry of both labels into the cytoplasmic compartment from the medium 
is visible after the first 15 minutes of incubation. From fifteen minutes on, the amount of both 
labels remains relatively constant within the acid soluble fraction as well as the medium at 
about 20% and 80% respectively. After 120 minutes there appears to be a slight decrease in 
the amount of both labels in the acid soluble cytosolic components matched by an equal 
increase in the amount of both labels in the medium. The incorporation of both labels into 
acid precipitable material appears to increase in a linear fashion from the start of the 
experiment up to two hours suggesting a more or less constant rate of protein synthesis. The 
amount of label incorporated into acid precipitable material only reaches about 1 % of the total 
amount of label added. The ratio of 
3H/35S stayed constant at -1 for all three compartments 
over the two hour period. 
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Methionine-free Eagles Minimal Essential Medium (MEM) was subsequently tested to 
ascertain the effect that a more complete medium would have on labeling. The medium was 
also supplemented with 1 mg/L methionine to test whether the absence or presence of 
methionine has a profound effect on the metabolism and labeling of the cultured cells. 
Virtually identical results were obtained in the presence and absence of the added methionine 
and it appeared that the dilution of the radiolabeled methionine with unlabeled methionine 
was not a significant problem as there was only a 50% reduction in the amount of radiolabel 
incorporated into acid precipitable material. The results for the methionine-free MEM 
supplemented with 1 mg/L methionine are shown in Figure 23. The overall trend is similar to 
the first experiment with two important exceptions. Firstly, the amount of label that enters the 
acid soluble fraction is only about 0.5% of the total amount of label, in contrast to the 20% in 
the first experiment. Both these findings were reproducible. Interestingly, the incorporation of 
both labels into acid precipitable material was still linear and reached about 1 % of the total 
amount of label as in the previous experiment. Secondly, the ratio of 
3HP5S in the acid 
soluble fraction increases markedly over the two hour time course of the experiment. This 
was not observed in the first experiment where the ratio of the two labels stayed constant for 
all three fractions. The ratio of 3HP5S in the medium and acid precipitable fractions remained 
completely constant over the two hour time period. 
The dual label assay was then applied to investigate known homozygotes, heterozygotes and 
control lines in an attempt to find possible differences in the ratio of the two labels in any of 
the fractions. The homozygous cell lines were obtained from two siblings (patients 488 and 
489) who were compound heterozygotes for CBS deficiency with the same mutant CBS 
genotype that completely abolishes enzyme activity. The heterozygotes were their parents 
(patients 486 and 487) who each carried one of the two compound mutations present in their 
offspring. The general trend of the results obtained for each of the cell lines was almost 
identical to the previous experiment illustrated in Figure 23. There is an initial increase of 
label in the acid soluble pool, which flattens of after 15 minutes. The incorporation of both 
labels into acid precipitable material is linear over time and the ratios of 
3H/35S in the medium 
and the acid precipitable fraction stayed constant for the duration of the assay. As in the 
second experiment there is a marked increase in the ratio of 
3HP5S in the acid soluble fraction 
over the time course of the experiment. The ratio of 
3Hi35S in the acid soluble fraction is 
illustrated in Figure 24 for each of the cell lines. It is clear that there is no correlation between 
the rate of change in the ratio of 3HP5s in the acid soluble fraction and the zygosity of the cell 
line for CBS deficiency and that the change in ratio of 
3HP5S in the acid soluble fraction over 
time can therefore not be used as an indicator for CBS deficiency. These investigations, 
however present only pilot studies on the use of dual metabolic labels in the investigation of 
methionine metabolism and much further work is needed before a definite indication of the 
usefulness of this technique in this regard can be ascertained. 
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Figure 21. Summary of methionine metabolism, illustrating into which metabolites the ""S (orange) 
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Figure 22. Dual label of a control cell line in Medium Z containing 1 mg/L glucose. The top figure 
represents the medium, the middle figure the acid soluble pool and the bottom figure the acid 
precipitable material. The yellow circles represent 35S, while the white circles represent 3H. 
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Figure 23. Dual label of a control cell line in methionine free MEM supplemented with 1 mg/I 
methionine. The top figure represents the medium, the middle figure the acid soluble pool and the 


























Figure 24. Ratio of "H~ S in the acid 
soluble pool over time. The circles represent 
two compound heterozygotes siblings for 
CBS deficiency with the same genotype, the 
triangles their heterozygote parents and the 
squares two control cell lines. No difference 
in the change in ratio is observed between 
the three groups. 
DISCUSSION 
Hyperhomocysteinaemia is an established independent risk factor for the development of 
vascular disease. In a study of over 600 patients with homocystinuria due to CBS deficiency, 
51 % of the 158 thromboembolic events that occurred were in the peripheral veins (Mudd et al, 
1985). Two separate studies (Boers et al, 1985 and Clarke et al, 1991) also found mild 
hyperhomocysteinaemia in 28% of subjects suffering from peripheral vascular disease. Boers 
also measured decreased CBS activity in all the hyperhomocysteinaemic subjects studied. 
Den Heijer et al (1996) recently found a greatly increased probability of the occurrence of 
deep-vein thrombosis in subjects with mild hyperhomocysteinaemia. Our study focussed on 
the incidence of CBS deficiency in subjects with peripheral vascular disease that had none of 
the conventional risk factors for the development of vascular disease and were selected for 
having hyperhomocysteinaemia. The study group of 12 young patients was of varied ethnic 
and racial origin. Although the hyperhomocysteinaemia may have contributed to the vascular 
disease in these patients, it is important to note that other factors, such as genetic defects in 
Factor V could also have contributed to the development of vascular disease in this group of 
patients (Mandel et al, 1996). 
Plasma homocysteine levels 
Fasting plasma homocysteine measurements revealed that 6 of the 12 PVD patients suffered 
from mild hyperhomocysteinaemia (Table 1). The measurement of plasma homocysteine 
levels after an oral methionine load was developed to identify heterozygotes for CBS 
deficiency (Fowler et al, 1971) and clinical studies have shown that the methionine loading 
test can identify subjects that are missed by measuring only fasting plasma homocysteine 
(Graham et al, 1997). Two of the subjects with mildly elevated fasting plasma homocysteine 
were not available for methionine loading. Three of the four remaining subjects with mild 
fasting hyperhomocysteinaemia also showed abnormally elevated plasma homocysteine 
levels after methionine load, as ascertained by the absolute value as well as the increase in 
plasma homocysteine. All six PVD patients who had normal fasting plasma homocysteine 
levels displayed hyperhomocysteinaemia after methionine load as measured by the absolute 
value and/or the increase from the fasting level. Thus nine out of ten subjects that had the 
methionine loading test done showed hyperhomocysteinaemia, indicating that defects in the 
transsulfuration pathway, such as heterozygosity for CBS deficiency might play an important 
role in this population. 
Standardization of the CBS assay 
The initial stumbling block in this project was that the CBS assay had been found to yield 
unreproducible results from one assay to the next in previous studies done in our laboratory. 
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The assay needed to be standardized and the sources of variation identified and eliminated 
before it could be applied to the study population. 
Digitonin treatment was investigated as a mild method of cell lysis that would preferentially 
release cytoplasmic components and leave organelles intact. This method of lysis would 
leave lysozomes intact, which contain proteolytic enzymes that might cause variations in 
enzyme activity. Using citrate synthase as a mitochondrial marker and lactate 
dehydrogenase as a cytoplasmic mark.er it was found that Digitonin treatment releases about 
25% less of the cytoplasmic components compared to freeze/thawing and sonication 
(Figure 2). Digitonin treatment however released five and ten times less citrate synthase 
activity than freeze/thawing and sonication respectively. Digitonin treatment reproducibly 
released both protein and CBS activity from trypsinized fibroblast suspensions and left a 
constant amount of CBS activity associated with the cellular debris (Table 3). 
Separation of reaction products by TLC was compared to separation by amino acid analyzer 
(Table 2). The enzyme activity obtained with separation by TLC was consistently about 10% 
less than the enzyme activity obtained with separation by amino acid analyzer. The 
difference between the two methods was acceptable in light of the saving in hands-on time. 
In both cases virtually no radioactive cysteine could be measured. 
The extent of the variation in enzyme activity over time was investigated by seeding three 
separate tissue culture flasks with an identical starting culture and assaying each of the three 
flasks in triplicate, every week for a period of five weeks (Figure 4). The results of this 
experiment showed a fourfold difference between the highest and lowest measured values 
between experiments. The variation between replicates of the same culture and between the 
separate cultures was very similar (-10%) and marginal compared to the variation between 
experiments. The variation between experiments did not correlate with the amount of protein 
released from the cells and showed a stronger association with the absolute amount of 
enzyme activity released from the cells. Importantly, the enzyme activity released from the 
cultures varied in tandem. Whatever factor/s caused the variation therefore affected all the 
cultures to the same degree. 
Various factors that could possibly contribute to the observed variation were investigated. 
The release of CBS activity by Digitonin had been found to be reproducible (Table 3) and the 
variation in the enzyme activity between different Digitonin lysates of identical cell 
suspensions was found to be the same as the variation between replicate of identical lysates 
(Table 5). The variation between different substrate solutions was also found to be 
comparable to the variation between replicate of identical lysates (Table 2). The Biorad 
protein assay was found to be very reproducible and to make only a minor contribution to the 
overall variation. Contaminating protein from the fetal bovine serum in the tissue culture 
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medium contributed little to the protein measurements, as washing the cell pellet with PBS 
had no effect on the enzyme activity (Table 4). 
The reproducibility of the assay procedure itself was investigated by freezing away identical 
cell pellets and lysates of thereof and assaying these over a period of two weeks (Figure 5). 
The culture from which the cell pellets and lysates were obtained was maintained and also 
assayed. The results indicated that the assay was reproducible. The assays on the frozen 
lysates and fresh lysate of the frozen cell pellets did not vary markedly. The frozen cell 
pellets reproducibly showed -10% more activity than the lysates indicating that the freezing 
and thawing of the cell pellets released additional enzyme. The assays on the lysates of the 
original cultures that were maintained over the time of the experiment showed the same 
fourfold difference between the highest and lowest value as was found initially, suggesting 
that factors during the culture of the cells made the greatest contribution towards the 
variation. 
The density of the cultures seemed a likely source of variations in the levels of expression of 
the enzyme. All the previous experiments had been performed on cultures that had just 
reached confluence or that were sub-confluent. Equal amounts of a cell suspension were 
seeded into eight tissue culture flasks and the cultures were allowed to reach a highly 
confluent state. Two flasks where trypsinized, lysed and assayed each week for four weeks 
(Figure 6). The results from this experiment showed that once the cultures had reached 
confluence, the amount of measurable enzyme activity remained stable and all subsequent 
experiments were performed on highly confluent cultures. 
The kinetic properties of the enzyme in the assay were also investigated to establish the 
conditions under which maximal activity could be obtained. The Km for serine in the assay 
was determined to be 10.2mM using a Michaelis-Menten fit and 7.2mM using a reciprocal 
Lineweaver-Burk plot (Figure 7). These values correspond well with the published value of 
4mM obtained for the enzyme purified from human liver. The assay showed substrate 
inhibition with respect to homocysteine (Figure 8). Product inhibition was excluded by 
assaying in the presence of increasing cystathionine, which had no effect on CBS activity. 
Maximal enzyme activity was obtained at 20mM homocysteine and the Km calculated as 
8.4mM by fitting a curve to the data using an equation describing substrate inhibition. 
Fleisher et al (1973) reported similar data but did not comment further. A possibility that 
cannot be excluded and that was not tested was that other substances in the homocysteine 
preparation caused the observed inhibition and not the homocysteine itself. Maximal enzyme 
activity was achieved at 0.25mM pyridoxal 5-phosphate, as there was no change in activity 
between 0.25mM and 2mM PLP. 
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The conditions under which maximal activity was obtained were defined as 20mM 
homocysteine, 40mM serine and 2mM PLP. Propargylglycine, an inhibitor of y-cystathionase 
was added to SmM and S-adenosylmethionine and allosteric activator of CBS was added to 
1 mM. The addition of 1 OOµM SAM has been shown to stimulate CBS activity threefold 
(Kluijtmans et al, 1996). The conditions of sub-maximal activity were adapted from Fowler et 
al (1978) and were defined as 1 OmM homocysteine and SmM serine. 
CBS activity in the PVD group 
The standardized enzyme assay was subsequently applied to the PVD patient population. A 
control group consisting of age and sex matched subjects with no indication of disorders of 
methionine metabolism was assayed as well as known homozygotes for CBS deficiency and 
their obligate heterozygote parents. The enzyme assay showed the best discrimination 
between the heterozygote and control subjects under conditions of sub-maximal enzyme 
activity (Figure 9, top & middle). Under conditions of maximal activity, the residual activity in 
the heterozygote patients was stimulated to such a degree that all the values obtained for this 
group fell within the control range, making these conditions unsuitable for distinguishing 
between heterozygotes for CBS deficiency and normal subjects. Under these conditions, no 
significant difference was observed between the enzyme activity measured in the PVD group 
and the control subjects. 
Under conditions of sub-maximal activity the overlap between the control and obligate 
heterozygotes was substantially less and the difference in enzyme activity between the two 
groups was significant (P<0.01). The 95% confidence interval for the control group was 
between 2.1 and 12.1 U/mg, which agrees well with previously published normal ranges 
established using similar conditions (Fowler et al, 1978 and Kluijtmans et al, 1996). Most 
importantly, the enzyme activity measured in the PVD patient population was significantly 
different from the control group (P<0.05). The values obtained under conditions of maximal 
activity correlated well with the values obtained under conditions of sub-maximal activity, with 
a correlation coefficient of 0.76 (Figure 10). 
On average the enzyme activity was about 6 times higher using the conditions of maximal 
enzyme activity. This increase in activity is most likely due to an estimated threefold increase 
in enzyme activity when adding S-adenosylmethionine to 1 mM, as reported by Kluijtmans et 
al (1996), as well as an estimated 2.5 fold increase in activity when increasing serine from 5 
to 40mM, using the values obtained from the serine titration. The addition of 2mM pyridoxal 
5-phosphate and the increase in homocysteine from 10 to 20mM also make lesser 
contributions to the increase in activity. 
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Repetition of the experiment under conditions of sub-maximal activity (Figure 9, bottom) 
however, revealed that CBS activity measured in lysates of fibroblast cultures was not 
reproducible. The correlation coefficient between the CBS activity measured on the two 
occasions was <0.5 for both the control and PVD groups (Figure 11), even though the CBS 
activity in the PVD group was not significantly different (P>0.75) between the two experiments 
and the range of values nearly identical. The CBS activity in the control group was however 
significantly lower in the second experiment compared to the first. Most importantly though, 
CBS activity was not significantly different between the control and PVD groups in contrast to 
the first experiment. 
Therefore, the assay still yields unreproducible results from one assay to the next in spite of 
all the efforts to standardize it. It would seem that the individual values vary, but the overall 
trend remains the same, as CBS activity measured in the obligate heterozygote group was 
still significantly lower than the controls, and homozygotes showed very little activity. The 
most appropriate way of identifying heterozygotes under these circumstances is to assay for 
CBS activity in patients and a group of controls on more than one occasion. If the measured 
enzyme activity is consistently low compared to the control group, it is highly likely that the 
patient is a heterozygote for CBS deficiency. 
Only one patient in the PVD group, patient 1000 truly fulfilled these criteria. Low CBS activity 
compared to controls was measured in lysates of fibroblasts of this patient on three separate 
occasion under both conditions of maximal and sub-maximal activity, and this patient 
consistently showed the lowest CBS activity in the PVD group. It is not surprising to find that 
patient 1000 consistently showed significantly reduced CBS activity as the patient had the 
second highest fasting and post methionine-load plasma homocysteine levels in the group of 
PVD patients. Intriguingly patient 983, who had the highest fasting and post methionine-load 
plasma homocysteine levels in the group, showed highest CBS activity (6.3U/mg) in the first 
experiment. The second CBS assay on this patient was much lower (3.3U/mg). Most 
patients typically showed moderate CBS activity in one or both of the assays. The fact that 
the CBS activity measured in fibroblasts is not reproducible made it nearly impossible to truly 
state whether or not some of the subjects are not in fact heterozygous for CBS deficiency. An 
asymptomatic obligate heterozygote mother (959) of a homocystinuric patient (960) showed 
variable CBS activity (5.1 and 2. 7U/mg) very similar to what was found for patient 983. This 
patient would have been excluded under the criteria applied to the study group and most of 
the PVD patients can therefore not with certainty be excluded as possible heterozygotes for 
CBS deficiency. It is important to note that in a similar study by Boers et al (1985), reduced 
CBS activity compared to controls was measured in all seven of the hyperhomocysteinaemic 
patients with peripheral vascular disease. It is possible that the different findings in this study 
and the study by Boers et al are the result of the strict criteria applied to the patient 
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population, or that differences are the result of varying incidence of CBS deficiency in two 
populations of different ethnic origin. 
The possibility remains that defects in enzymes other than CBS are the cause of the 
hyperhomocysteinaemia in these patients. The thermolabile variant of MTHFR causes mild 
hyperhomocysteinaemia and has been shown to occur with a frequency of -10% in the 
Caucasian population (Rosenblatt, 1995), but could not be associated with vascular disease 
(Brattstrom et al, 1998). Defects in methionine synthase or other disorders of cobalamin 
metabolism are other possible causes of hyperhomocysteinaemia. These enzyme defects 
were not assayed for in any way. Nutritional deficiencies of 86, 812 or folate could also have 
made a contribution to the observed hyperhomocysteinaemia (Robinson et al, 1998), but 
would not have been reflected in the CBS assay, as it is performed on material isolated from 
cultured cells, grown in medium that is supplemented with vitamin cofactors. Only genetic 
defects in the metabolism of the vitamin cofactors would have yielded reduced enzyme 
activity. It is also possible that some patients may have reduced CBS activity in vivo, which is 
not detected using material obtained from cultured cells, as culture conditions not represent 
in vivo conditions accurately. 
The exact source of the variation still remains unclear. Most factors that might influence the 
activity of the enzyme in the assay procedure itself were investigated and found to have a 
minor effect. The assay procedure itself was also found to be reproducible both on the same 
occasion and on separate days. The only aspect that seemed likely to influence the activity to 
a large extent was the tissue culture conditions. It was initially thought that the confluence of 
the cultures was the most influential factor on the CBS activity. Experimental evidence also 
showed that after cultures had reached confluence that the activity remains stable (Figure 6). 
Even though highly confluent cultures were used in the investigation of the PVD group, the 
CBS activity was still not reproducible (Figure 11). 
It is possible that factors beyond experimental control are responsible for the large 
inter-experimental variation, and as CBS is mainly expressed in liver (Mudd et al, 1995), the 
expression of CBS is possibly not as tightly controlled in extra hepatic tissues. CBS activity is 
detectable in fibroblast cells grown from skin, but not in homogenized skin 
(Uhlendorf et al, 1968), and is much less in fibroblasts than in homogenized liver. Liver 
biopsy material would also reflect the in vivo status of the patients much more accurately than 
fibroblasts grown in culture. Fibroblasts however, have to substitute as a less optimal starting 
material, as liver biopsies are difficult and risky to obtain. Whatever the source of the 
variation, it makes it very difficult to identify heterozygotes for CBS deficiency, especially 
when the overlap in the ranges of activities measured in controls and heterozygotes is taken 
into account. 
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The association of CBS activity measured in lysates of cultured fibroblasts with the fasting 
and post methionine load plasma homocysteine levels was also investigated. Scatter plots of 
fasting and post methionine load plasma homocysteine as well as the change in plasma 
homocysteine versus CBS activity measured under conditions of maximal and sub-maximal 
activity are illustrated in Figure 12. A slight negative correlation is noted between the fasting 
and post methionine-load homocysteine levels and CBS activity under both conditions of 
maximal activity as well as conditions of sub-maximal activity in the first experiment. This 
type of correlation is to be expected as subjects with higher CBS activities will process 
homocysteine more rapidly and reduce its concentration in plasma. No correlation between 
plasma homocysteine levels and CBS activity is apparent in the second experiment. The 
reason for the weak correlation between plasma homocysteine levels and CBS activity might 
be related to the fact that plasma homocysteine levels, measured in vivo, is the product of 
many genetic loci, while CBS activity, measured in vitro under controlled tissue culture and 
assay conditions, is only the product of one genetic locus. Dawson et al (1996) has provided 
evidence that even in family members with an identical genotype for defects in the CBS 
coding sequence, the phenotype for plasma homocysteine levels might be different. 
Molecular investigations 
The aim of the molecular techniques applied in this research was to identify the exact genetic 
mutations in the CBS coding sequence causing reduced enzyme activity and ultimately 
hyperhomocysteinaemia. The subjects that were investigated were patient 1000, a likely 
candidate for CBS deficiency based on plasma homocysteine measurements and CBS 
activity in cultured fibroblasts, patient 960, suffering from severe homocystinuria and her 
asymptomatic mother, patient 961. 
The initial approach was to directly sequence PCR amplified cDNA that was reverse 
transcribed from mRNA, isolated from cultured fibroblasts of the patients. Two rounds of PCR 
using nested primers was necessary to obtain a sufficient quantity of PCR product due to the 
fact that the CBS gene is expressed at low levels in fibroblast cells (Figure 13). Nested PCR 
greatly enhances the specificity of PCR as two different sets of primers are used in the 
successive amplifications. PCR products were gel purified using commercial kits and 
sequenced using internal primers and dye labeled terminators. This approach proved to be 
unsuccessful as Taq polymerase could introduce single base changes in the PCR product 
due to a lack of proofreading activity. Sequencing of PCR products also screens both alleles 
simultaneously, causing point mutations to show up as double peaks or bands. By the nature 
of the sequencing reaction, numerous double peaks or bands are present, making it virtually 
impossible to distinguish the true mutations. 
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These difficulties were overcome by cloning the PCR amplified CBS cDNA. This allows for 
the sequencing of one allele at a time. The entire coding sequence of the CBS cDNA was 
amplified and ligated into pGEM-T and used to transform RbCl2 competent E.coli (Figure 14). 
The pGEM-T vector was chosen as it allows for the convenient direct ligation of PCR product 
into the vector. It contains single overhanging 5' thymidines which are complementary to 
single 3' adenines on the PCR product created by Taq polymerase's terminal transferase 
activity. RbCl2 treatment was chosen as a method for producing competent E.coli as it yields 
very reproducible transfonnation although at a lower efficiency than electroporation. High 
transfonnation efficiency is not a prerequisite when cloning PCR amplified DNA, as a high 
number of copies of the gene are present. Also, when screening for mutations, only two 
alleles need to be found. Twenty insert-containing clones are usually more than sufficient to 
find more than one copy of the mutant allele. The whole system once standardized worked 
very effectively. 
Sequencing of the clones was perfonned using fluorescently labeled M13 -40 forward and 
reverse sequencing primers. This type of approach usually allowed 750bp to be read in the 
forward and reverse directions, leaving the middle 500bp of each clone unsequenced. These 
bases were sequenced using internal primers and fluorescently labeled tenninators. 
Patient 960, an adolescent female who suffered from severe homocystinuria was confinned to 
be a compound heterozygote for CBS deficiency. One allele carried the commonly occurring 
G to A transition at nucleotide 919 resulting in the substitution of glycine for serine at amino 
acid 307 (G307S). Sequencing confinned this mutation to be present in one clone as well as 
the cDNA of the patient (Figure 18). This is the most common mutation in the CBS coding 
sequence in populations of Celtic origin and is associated with 86 non-responsiveness in vivo 
and complete loss of enzyme activity (Hu et al, 1993). This mutation creates an A/ul 
restriction enzyme digest site, which was used to confirm the presence of the mutation in 
three clones as well as the patient's cDNA (Figure 19). The other allele carried a duplication 
of the 7 bases between nucleotide 1553 and 1559. This 7 base pair insert results in a reading 
frame shift, altering the amino acid sequence from position 519, as well as the premature 
introduction of a stop codon, truncating the protein by 12 amino acids. This drastic change in 
primary amino acid sequence most likely has a severe impact on the protein structure and 
function as virtually no enzyme activity could be detected in this patient. This sequence 
change could also negatively impact on the ability of the protein to fonn active tetramer. The 
last 137 amino acids have been illustrated to be important for tetramer fonnation by trypsin 
cleavage of the enzyme (Kery et al, 1998). The severe clinical condition of the patient is 
substantiated by the profound effect that both mutations have on the enzyme activity. 
Sequencing revealed that the patient inherited the allele containing the 7bp duplication from 
her mother. Restriction digest analysis also revealed that the mother did not carry the G91 gA 
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transition (Figure 19). The mother was completely asymptomatic, had moderate CBS activity 
in lysates of fibroblast cultures and her plasma homocysteine status is unknown. The 
moderate activity is probably sufficient to maintain normal plasma homocysteine 
concentrations and avert the development of disease. The fact that this mutation probably 
directly impairs the ability of the mutant protein to form tetramer most likely mitigates the 
dominant negative interaction between mutant and normal subunits, since only tetramer 
composed of normal subunits will be formed to an appreciable degree. This could possibly 
explain the presence of a moderate amount of residual enzyme activity in the mother. 
Patient 1000 showed definite fasting and post methionine load hyperhomocysteinaemia as 
well as markedly reduced CBS activity compared to controls on a number of occasions and 
was therefore a likely heterozygote for deficiency of this enzyme. The same sequencing 
approach as outlined above was used. An A to G transition was identified at nucleotide 695 
in two clones out of seven sequenced clones. No other mutations were consistently found in 
any of the remaining clones. This mutation leads to the substitution of a histidine for an 
arginine at amino acid 232 (H232R). The sequencing profile for the normal and the mutant 
alleles are illustrated in Figure 20. The arginine to histidine substitution, although not 
changing the polarity of the amino acid side chain, does substitute a long aliphatic chain for a 
bulky cyclic group. This moderate character change in the amino acid side chain is consistent 
with the preservation of a fair amount of enzyme activity in this patient. 
Hyperhomocysteinaemia combined with reduced CBS activity compared to controls does not 
in all cases seem to indicate genetic defects in the CBS coding sequence. Kozich et al 
(1995) measured the activity of the gene products of single CBS alleles purified form an E.coli 
expression system, obtained from patients with occlusive arterial disease, 
hyperhomocysteinaemia and reduced CBS activity in fibroblasts. They could not find reduced 
activity in seven of the eight individual alleles from four patients, and direct sequencing of 
both alleles of one of the patients yielded no pathogenic mutations. Mutations in the 
untranslated or promoter regions of the CBS gene, which were not sequenced could have 
contributed to the reduced enzyme activity. Another possibility is that the criteria applied are 
not strict enough for the correct identification of heterozygotes for CBS deficiency. 
Dual metabolic labelling 
The metabolism of methionine in cultured fibroblasts was investigated using two radiolabeled 
isotopes of methionine. L-[
35S]-methionine was used to follow methionine through the 
transsulfuration and remethylation pathways, while L-[methyl-
3H]-methionine was used as a 
marker for methyl transfer reactions. Figure 21 shows the metabolism of methionine with the 
metabolites that the 
35S (yellow) and tritium (blue) labels can be incorporated into. The 
35S 
radiolabel can be incorporated into protein directly as methionine or after being metabolized 
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through the transsulfuration pathway, as cysteine. The tritium radiolabel, is on the meth
yl 
group of methionine and is transferred to a methylated acceptor, including nucleic acid an
d 
protein. It can also be incorporated directly into protein as methionine. Changes in the flu
x 
through the transsulfuration and remethylation pathways, such as caused by enzym
e 
deficiencies, could therefore affect the ratio of tritium to 
35S as well as the absolute amount of 
each label incorporated into acid precipitable macromolecules as well as acid soluble sm
all 
molecular components. 
Confluent fibroblast cultures were incubated in pre-warmed buffer or tissue culture med
ia 
containing the isotopes. At various time intervals culture medium was removed, protein an
d 
DNA precipitated with 5% trichloracetic acid and the precipitated material released with O.S
M 
NaOH. The medium, acid soluble pool and acid precipitable pool at each time point we
re 
counted in a scintillation counter. A O to 200keV window was used to detect tritium (whic
h 
includes a defined contribution from 
35S) and a 400 to 600keV window was used to detect 
only 35S. The amount of each isotope was calculated for the medium, the TCA solub
le 
fraction containing all the small molecular components and the TCA precipitate
d 
macromolecules. 
Initially, experiments were performed to investigate the effects of different types of tissu
e 
culture media and buffers on the uptake and incorporation of the two labels into ac
id 
precipitable material (Figure 22 and 23). Essentially, two types of media were investigate
d, 
Medium Z, a balanced salt solution containing 1 g/L glucose as a carbon source as well 
as 
methionine-free Eagles minimal essential medium (MEM). The methionine-free MEM w
as 
supplemented with 1 mg/L unlabeled methionine, to avoid its depletion in the medium durin
g 
the course of the assay as the labels make a very small quantitative contribution to t
he 
amount of methionine present in molar terms. Overall, the addition of 1mg/L unlabele
d 
methionine had little effect on the overall uptake and incorporation of either label, and dilute
d 
the radiolabeled methionine fifteen-fold less than normal MEM, which contains 15mg/L 
methionine. 
The overall trend in the uptake and incorporation of both labels was very similar whether th
e 
incubation was done in Medium Z or methionine-free MEM supplemented with 1 mg
/L 
methionine. In the first fifteen minutes there is a sharp increase in the amount of both labe
ls 
in the acid soluble fraction (Figure 22 and 23, middle panels), accompanied by a simil
ar 
reduction in both labels in the medium (top panels), illustrating the uptake of the labels in
to 
the cells. The amount of both labels subsequently stabilizes in the acid soluble fraction a
nd 
the medium after fifteen minutes. It is possible that influx simply ceases, although it is diffic
ult 
to provide a reason therefore, or that a steady state between influx and efflux of both labels
 is 
achieved which is more likely. Influx and efflux of the labels could occur as methionine, or th
e 
methionine could be metabolized to different compounds, which could then be exported fro
m 
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the cells. In contrast to this, a linear increase in the amount of both labels incorporated into 
acid precipitable macromolecules is apparent (bottom panels). 
Two important differences where observed. Firstly, the fraction of both labels that entered the 
acid soluble pool from the medium was about 30 times higher when Medium Z was used 
(0.20) compared to when methionine free MEM supplemented with 1 mg/L methionine was 
used (0.006). Secondly, the ratio of 
3Ht35S in the acid soluble pool steadily increased when 
the cells where incubated in methionine free MEM supplemented with 1 mg/L methionine, 
while the amounts of tritium and 
35S remained almost identical when the cells where 
incubated in Medium Z. Most importantly, the fraction of the labels that was incorporated into 
acid precipitable material was almost identical in both media, regardless of the fact that about 
thirty times more label was present in the acid soluble pool when the cells were incubated in 
Medium Z. Methionine-free MEM supplemented with 1 mg/L methionine was chosen for 
subsequent investigations as it is a more complete medium which will be less likely to lead to 
deficiencies that could alter the normal metabolic flux in the cultured cells. 
The dual label assay was subsequently applied to known homozygotes and heterozygotes for 
CBS deficiency. Fibroblasts from two homocystinuric siblings with identical CBS genotypes 
(patients 488 and 489) and their obligate heterozygote parents (patients 486 and 487) as well 
as two control cell lines were compared. Overall, the results of this experiment looked almost 
identical to the first control experiment with methionine-free MEM supplemented with 1 mg/L 
methionine. The ratio of 
3Ht35S in the medium and acid precipitable pool remained constant 
over the time course of the experiment and was not different between the homozygotes, 
heterozygotes and controls. The ratio of 
3Ht35S in the acid soluble pool (Figure 24) showed 
the same increase over time, but was also not different between the three groups. Neither 
the ratio of 3Ht35S in the acid precipitable pool or the acid soluble pool is therefore useful as a 
marker for the zygosity of the cell line for CBS deficiency, under these conditions. 
These investigations, however present only pilot studies on the use of dual metabolic labels in 
the investigation of methionine metabolism and much further work is needed before a definite 
indication of the usefulness of this technique in this regard can be ascertained. The 
metabolites in each pool can be separated chromatographically to gain further insight into the 
identity of the metabolites carrying the labels. The acid precipitable macromolecules can be 
hydrolyzed and separated and perhaps other ratios such as the ratio of the amount of 
35S 
incorporated as methionine to the amount of 
35S incorporated as cysteine can be used as 




This study explored the incidence of CBS deficiency in a group of twelve young patients of 
varied ethnic origin, with peripheral vascular disease that could not be ascribed to any of the 
conventional risk factors for the development of vascular disease and who were selected for 
having hyperhomocysteinaemia. 
The CBS assay proved to be highly variable despite all efforts to standardize the assay. The 
source of the variation could not be pinpointed, but seems to be related to varying physiology 
of the cell cultures over time, as the assay is reproducible when replicates of the same lysates 
are analyzed, even on different days. All other factors tested, such as varying substrate 
solutions, the protein assay, or the lysis of the cells appeared to contribute little to the very 
wide variation in CBS activity over time. Conditions under which maximal CBS activity could 
be obtained were defined, but proved to be less effective in distinguishing heterozygotes from 
normal subjects, compared to conditions of sub-maximal activity, with substrate 
concentrations below their Km for the enzyme. 
Only one out of the twelve patients assayed could truly be identified as a heterozygote for 
CBS deficiency (patient 1000) by repeatedly having low enzyme activity compared to controls. 
Under the strict criteria applied to the PVD population, however some of the heterozygotes for 
CBS deficiency could have been missed, as the obligate heterozygote mother (patient 961) of 
a homocystinuric patient (patient 960) showed CBS activity very similar to subjects in the PVD 
group. The hyperhomocysteinaemia measured in the other patients could also be due to 
defects in methionine synthase or MTHFR, or nutritional deficiencies of 86, 812 or folate 
which would not have been detected by the CBS assay. 
Selected patients were sequenced to detennine the exact genetic mutations causing the 
reduced enzyme activity. An A to G transition at nucleotide 695 leading to histidine to 
arginine substitution at amino acid 232 was found in one allele of patient 1000. A young 
homocystinuric female (patient 960) was confinned to be compound heterozygote for CBS 
deficiency, with the common Celtic GwiA transition on the one allele and a duplication of the 
7 bases between position 1553 and 1559 on the other allele, which was of maternal origin. 
Dual metabolic labeling of cultured fibroblasts with L-[methyl-
3H]-methionine and 
L-[35S]-methionine was also investigated as a possible method of identifying heterozygotes for 
CBS deficiency more effectively. The ratio of 
3H/35S was however not different in either the 
medium, the acid soluble pool or acid precipitable pool between controls, heterozygotes and 
homozygotes for CBS deficiency. These studies represent merely pilot experiments, and 
much work can still be done to investigate methionine metabolism by development of this 
approach. 
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In conclusion, the very wide between-experimental variation observed in the CBS assay was 
investigated and is most likely the result of changes in enzyme activity during cell culture. 
This variation suggests that reduced enzyme activity must be measured on several occasions 
compared to a control group, before a patient can be identified as a heterozygote for CBS 
deficiency. By applying the assay to a group of twelve PVD patients with 
hyperhomocysteinaemia, only one patient was shown to have CBS deficiency, which was 
confirmed on a genetic level. 
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